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INTRODUCTION
STUDY ON CARDIOVASCULAR MANIFESTATIONS
IN LUPUS PATIENTS
INTRODUCTION
 Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease
primarily occurs in young women and characterised by varied clinical and laboratory
manifestations. Severity ranges from a mild disease with rash and arthritis to a devastating
illness with renal failure and central nervous system involvement.  Perhaps because of the
prominence of cutaneous, musculoskeletal, renal and neurological manifestations cardiac
involvement has not received detailed attention. The widespread use of modern
echocardiography together with the longer life spans of severe SLE patients has contributed
to increased recognition of cardiovascular involvement in these patients.
 The heart is frequently involved in systemic lupus erythematosus (SLE). Cardiac
involvement in patients with SLE has been described since the early 20th century (1). In
recent years, echocardiography has yielded additional information about the heart in patients
who have SLE with and without clinical cardiac involvement. Echocardiography is a
sensitive and specific technique in detecting cardiac abnormalities, particularly mild
pericarditis, valvular lesions and myocardial dysfunction .Very sensitive methods of
cardiovascular investigation have found the prevalence of cardiac involvement in SLE to be
higher than50 %( 2, 3).
 SLE can affect most parts of the cardiovascular system. The pathologic
involvement  includes  pericarditis  with  or  without  effusion,  myocarditis  sometimes  with
involvement of the conduction system and myocardial infarction secondary to coronary
arteritis or premature accelerated atherosclerosis. Finally, endocardial involvement in SLE is
of particular interest because of its complications which include thromboembolism, infective
endocarditis and ultimately the need for cardiac surgery. Since the original description by
Libman and Sacks of sterile vegetations (4), there are many reports of valvular lesions
occurring in SLE (5, 6, 7, and 8). Often however, particularly with currently improved
therapeutic options, these valve lesions may remain subclinical and produce no symptoms,
causing no murmurs of regurgitation or stenosis and thus have no hemodynamic significance.
Echocardiography and Doppler with colour flow imaging are currently the only techniques
that can detect these lesions during life and better assess the entire spectrum of cardiac
pathology.
SLE patients have an increased prevalence of subclinical atherosclerotic disease
detected using several modalities. Hypertension and diabetes mellitus are also more prevalent
in SLE and traditional risk factors, e.g. hypercholesterolemia, contribute to the development
of atherosclerosis in SLE. However, these risk factors alone do not explain the excess CHD
risk and after adjusting for traditional risk factors,   SLE itself remains independently
associated with both clinical and subclinical outcomes. Several lupus-related factors may
contribute to the development of accelerated atherosclerosis, for example, there is growing
evidence that atherosclerosis itself has a chronic inflammatory component. Premature
atherosclerosis is the most frequent cause of coronary artery disease (CAD) in SLE patients.
In addition to chronic inflammation, patients with SLE frequently have lupus
anticoagulant (LAC) or associated antiphospholipid antibodies (aPL). A high proportion of
SLE patients with cardiac abnormalities have been noted to have high levels of
anticardiolipin antibodies. Moreover, antiphospholipid antibodies have been linked to several
cardiac manifestations in patients with SLE, including valvular abnormalities and possibly
coronary artery disease and there is in vitro evidence that certain aPL may be pro-atherogenic
as well as pro-thrombotic. Corticosteroid therapy has also been associated with clinical and
subclinical disease in several studies (9).
Though the cardiovascular manifestations in SLE have been well documented in
literature, there are very few studies done in India addressing this issue. Hence this study was
undertaken to establish the frequency and associated risk factors for cardiovascular
manifestations in patients of SLE in our geographic area. Although antiphospholipid
antibodies (aPL) are associated with arterial and venous thrombosis in systemic lupus
erythematosus (SLE), the extent to which they influence other cardiovascular manifestations
is either controversial or uncertain.  This study was done to examine the relationships of aPL





Lupus is an autoimmune disease characterized by acute and chronic inflammation
of various tissues of the body. Autoimmune diseases are illnesses that occur when the body's
tissues  are  attacked  by  its  own  immune  system.  The  immune  system  is  a  complex  system
within the body that is designed to fight infectious agents, such as bacteria and other foreign
microbes. One of the ways that the immune system fights infections is by producing
antibodies that bind to the microbes. Patients with lupus produce abnormal antibodies in their
blood that target tissues within their own body rather than foreign infectious agents. Because
the antibodies and accompanying cells of inflammation can affect tissues anywhere in the
body,  lupus  has  the  potential  to  affect  a  variety  of  tissues  and  organ  systems.  Sometimes
lupus can cause disease of the skin, heart, lungs, kidneys, joints, and/or nervous system.
When only the skin is involved, the condition is called lupus dermatitis or cutaneous lupus
erythematosus. A form of lupus dermatitis that can be isolated to the skin, without internal
disease, is called discoid lupus. When internal organs are involved, the condition is referred
to as systemic lupus erythematosus (SLE).
HISTORICAL ASPECTS
The term lupus is attributed to the thirteenth century physician Rogerius, who
described the facial lesions that were reminiscent of a “wolf’s bite” (10). In 1851, Cazenave
applied the term lupus erythematosus for the first time to a disease described by his teacher
Laurent Biett (11). In 1845, von Hebra,  a  Viennese  physician,  used  butterfly  rash  to
describe the familiar malar rash of the disease. For most of the nineteenth century, lupus was
thought to be a dermatologic disease. Von Hebra, in his 1856 book, published the first
illustrations of the disease in the Atlas of Skin Diseases. However, when Moretz Kaposi
described the visceral forms of the disease in 1872, physicians began to suspect that this
disease was a more generalized form of the illness and the term acute disseminated was
included in the description (12). Kaposi proposed two types of lupus: disseminated and
discoid. In his early writings, he supposed that the disseminated form consisted of 1)
subcutaneous nodules, 2) arthritis, 3) lymphadenopathy, 4) fever, 5) weight loss, 6) anemia,
and 7) central nervous system involvement. In 1904, William Osler described two women
who developed renal failure within 10 months of the appearance of a facial erythema, which
in retrospect was the facial rash of von Hebra (13).
Osler described a number of other illnesses at the time, among them, Henoch
Schoenlein purpura and disseminated gonococcemia, which could be confused with the
lesions in the two women. In Vienna at this time, Jedasson described similar syndromes in a
few patients. Both he and Osler therefore established SLE as a distinct entity by the turn of
the century, even though many practitioners still thought of SLE as a form of skin
tuberculosis (14). Very typical cases of SLE were reported under a variety of names, and it
was not until the 1920s and 30s that the disease was well defined. The disease, at that time,
was carefully described by pathologists who studied the morbid anatomic changes that so
characterized someone with lupus.
The atypical bacterial endocarditis of Emmanuel Libman and Benjamin Sacks,
described in 1924, was a classic example of the pathology found in some patients with SLE
and were likely lesions associated with antiphospholipid antibody (4). Following that
description, George Baehr,  published  a  series  of  23  autopsied  cases  of  the  renal  wire  loop
lesions of lupus nephritis and described the solar sensitivity we know so well. Thus,
pathologists further elucidated the disease known as lupus. In 1936 Frieberg, Gross and
Wallach autopsied a young woman with lupus and no skin lesions, indicating that the disease
was not primarily a skin condition and was even less associated with tuberculosis.
Klempner, Pollack, and Baehr in 1941 suggested that collagen was a part of the disease
because of the many instances of fibrinoid necrosis that they found with the disease. This
gave rise to the name collagen disease as a grouping for all of the diseases that affected
connective tissue, a term that is not used widely today.
Hack and Reinhart were the first to describe the false-positive syphilis test in SLE
and in 1940 Keil similarly reported ten cases of SLE with false-positive syphilis tests.
Haserick and Lang wrote about an additional series of cases where the presence of the false-
positive syphilis serology predated the clinical lupus by up to eight years. In all of these
cases, the false-positive syphilis tests probably resulted from the presence of antiphospholipid
antibodies, the discovery of which was to take an additional 30 years. In 1955, Moore (15)
studied another 148 patients who were positive for syphilis and found that some 7%
developed lupus with time, whereas 30% had symptoms related to collagen vascular disease.
In 1949, Phillip Hench (16) discovered cortisone, and the future of the connective tissue
diseases changed. Rheumatoid arthritis patients and those with lupus erythematosus (LE)
were manageable, and “cures” were reported.
In 1943, Malcolm M. Hargraves, a hematologist at the Mayo Clinic, found peculiar
globular bodies taking purple stain in the marrow aspirate of a child with an undiagnosed
disease;2 1/2 years later he made a similar observation. Symptoms in a third case with this
finding, in 1946, suggested that this patient had SLE. Two important observations were made
in addition to the association of this unusual cell with the diagnosis of SLE: (a) more of these
cells were found when the specimen was not fixed immediately; and (b) two similar cells
needed to be differentiated. These findings were first reported in January 1948 (17). The tart
cell (named after a patient) is not disease specific. Its distinguishing feature is that the
secondary nucleus has retained definite chromatin structure.
The LE cell is practically always a mature neutrophilic polymorphonuclear
leukocyte  in  contradistinction  to  the  tart  cell  which  is  most  often  a  histiocyte.  John  R.
Haserick at the Cleveland Clinic suggested already in 1948 that the greatest value of the LE
cell lies in its possible presence in suspected cases of acute disseminated lupus erythematosus
in which the classic dermatologic manifestations are lacking (18). Hargraves (19) in 1949
demonstrated LE cells in the buffy coat of centrifuged specimens of peripheral blood of
patients in whose marrow LE cells had been detected. Since it was found to have poor
sensitivity and specificity reliability on the LE cell to diagnose SLE, began to diminish after a
few years.
In 1957, Friou et al. (20) at Yale devised a technique to demonstrate the antibody
semi quantitatively by indirect immunofluorescence microscopy. The reactive substance was
identified in 1959 as a DNA-histone nucleoprotein and Beck in 1961 in London showed that
at least three fluorescent staining patterns could be distinguished (21). In the next decade,
refined laboratory methods permitted the discovery of numerous antibodies, some of which
could be correlated clinically with subsets of SLE and other diseases. The discovery of the
LE cell had initiated the discipline of immunopathology.
In 1957, three laboratories almost simultaneously demonstrated a factor in the
serum of some cases of SLE that reacts specifically with DNA (22). Tan et al. (23) in 1966 in
New York detected anti-DNA antibodies in SLE sera. Koffler et al. (24) in 1969 in New York
found that the detection of native (double-stranded) deoxyribonucleic acid (dsDNA) is more
specific for SLE, but less sensitive than antibody to denatured (single-stranded) DNA. Schur
et al. (25) in 1971, using more sensitive techniques, confirmed the specificity of the reaction
with dsDNA, but obtained positive reactions in only one half of SLE sera. Tan and Kunkel
(26) in 1966 in New York detected a cytoplasmic (RNP) antigen in SLE serum that they
designated Sm. It was the first antibody to a nonhistone nuclear antigen and highly specific
for SLE, although found in only one third of cases.
The next discoveries about the antibody systems that related to SLE were gained
from the development of techniques to extract uncomplexed histones from nuclei and
recombining them with DNA, free of other components (27). Histones are small basic
proteins associated with nucleic acids in cell nuclei. Some extracted recombined antigens,
depending on the precise histone structure, can be used to detect antihistone antibodies. The
important findings were that antihistone antibodies occur more frequently in drug-induced
than in idiopathic SLE, and that lupus-inducing drugs vary in their ability to induce these
antibodies, procaine amide doing so most consistently (28).
The  role  of  antinuclear  antibodies  (ANAs)  in  SLE  became  uncertain  when
clinically typical cases in which ANAs could not be detected began to be described. These
cases comprise fewer than 5% of cases of SLE, and most have antibody reactive against the
cytoplasmic RNA antigen Ro (29).
The introduction in 1963 of a convenient pathologic technique complemented the
ever-increasing number of serologic tests. The lupus band test determines by
immunofluorescence microscopy of skin biopsies as to whether immunoglobulins are
deposited at the dermo-epidermal junction (30). In DLE it is positive in lesional but not in
uninvolved skin. It also is positive in the normal skin of at least half of cases of SLE, MCTD
and psoriasis (31). It has proven not to be a highly specific finding, since it occurs in about
15%  of  cases  of  rheumatoid  arthritis  (32)  and  in  various  bullous  dermatoses.  At  Otago
Medical School the NZ Brown X NZ White hybrid mouse was discovered (1959) to develop
a lethal kidney disease closely resembling Lupus Nephritis - the kidney disease which some
people with SLE develop. This mouse has since been studied in laboratories all around the
world. Other mice which develop Lupus-like diseases have also been bred particularly in the
United States. These mice have aided research tremendously.
EPIDEMIOLOGY
 One of the most striking features of SLE is its female predominance. The
importance of female hormones in the pathogenesis of SLE has been elegantly studied in
murine models (33). In humans, the ratio of women to men is 9:1, although in a recent study
from Rochester, Minnesota, the ratio was less (34). Women with SLE may metabolize
estrogen by using pathways that lead to elevated levels of the more active metabolite
hydroxyestrone, which would accentuate the effect of estrogen on the immune system (35).
Male SLE patients can have decreased androgen levels (36). Thus, an imbalance of estrogen-
to-androgen ratio may predispose to SLE in both sexes. The mechanism by which this
imbalance leads to autoimmunity is less clear, because sex hormones could act at multiple
levels. Sex hormones bind to receptors in the thymus and spleen and to receptors on
lymphocytes and increase mitogen-induced immunoglobulin production (37).
SLE is usually a post pubertal disease, with onset of clinical symptoms usually in
the 20s to 30s. Childhood and older-onset SLEs differ from the classic presentation, with less
female predominance and different clinical presentations. Younger-onset SLE (before age 20)
has an increase in cutaneous and renal SLE and is more likely have low serum C4 than older-
onset SLE. In a retrospective study of 31 children with SLE, arthritis,  anemia,  and seizures
were associated with a poor prognosis (38). Older-onset (older than 40 years) SLE is less
likely to have malar rash, proteinuria, and low serum C4, but more likely to have secondary
Sjogren's syndrome.
In both the United States and the United Kingdom (23), SLE is more common in
African Americans and African Caribbeans (39,40), yet SLE is not a common autoimmune
disease in Africa. SLE does appear to be common in Asia (41,42) and Latin America (43).
The LUMINA study in the United States has begun a comparison of SLE in Caucasians,
Hispanics, and African-Americans (44). Race affects both the presentation and the course of
SLE. Blacks with SLE are more likely than whites to have discoid SLE, lupus nephritis (45),
lymphadenopathy, myositis, and pericarditis, but less likely to have malar rash and mouth
ulcers. African-Americans are also more likely to have anti-ribonucleoprotein (anti-RNP) and
anti-Sm, but are less likely to have anticardiolipin and lupus anticoagulant than white
patients.
Differences in SLE presentation and course that are related to socioeconomic status
may actually be due to other factors. In a prospective study of predictors of poor renal
outcome (renal insufficiency, renal failure, and chronic nephrotic syndrome), socioeconomic
status and race were not found to be significant predictors. Instead, compliance (with visits
and medication) and hypertension were the major explanatory variables for poor renal
outcomes (45).
Education, however, was associated with major comorbidities of SLE, such as
cataracts, hypertension, peptic ulcer, and thrombosis, even after adjustment for race.
Education also was associated with several clinical manifestations, including discoid rash,
psychosis, and seizures. The apparent association of education with these factors may be due
to confounding variables such as diet and social habits.
Systemic lupus erythematosus is rare in India. A prevalence study in India (carried
out in a rural population near Delhi) found a point prevalence of 3 per 100,000 (46).This is a
much lower figure than reported from the west (Varying from 12.5 per 100,000 adults in
England to 39 per 100,000 in Finland and 124 per 100,000 in USA).However, a fair number
of cases of SLE are encountered in any large hospital in India. Copcord Bhigwan study (an
ongoing, prospective population study from Pune) found a crude incidence rate of 1 per
25,000 person years i.e.4per 100,000 population per year (personal Communication) (47).
Recent  work  from Rochester,  Minnesota,  indicates  that  the  incidence  of  SLE has
tripled since the 1970s, from 1.51 in 100,000 (1950-1979) to 5.56 in 100,000 (1980-1992)
(34). Prevalence of SLE in the United States is 15–50 per 100,000; the highest prevalence
among ethnic groups studied is in African Americans.
PATHOGENESIS
In SLE, interactions between susceptibility genes and environmental factors result
in abnormal immune responses. Those responses include 1) activation of innate immunity
(dendritic cells) by DNA, DNA in immune complexes, and RNA in RNA/protein self-
antigens; 2) lowered activation thresholds of adaptive immunity cells (antigen-specific T and
B lymphocytes);3) ineffective regulatory and inhibitory CD4+ and CD8+ T cells; and 4)
reduced clearance of apoptotic cells and of immune complexes. Self-antigens (nucleosomal
DNA/protein; RNA/protein in Sm, Ro, and La; phospholipids) are available for recognition
by the immune system in surface blebs of apoptotic cells; thus antigens, autoantibodies, and
immune complexes persist for prolonged periods of time, allowing inflammation and disease
to develop. Immune activation of circulating and tissue-bound cells is accompanied by
increased secretion of proinflammatory tumor necrosis factor (TNF) and type 1 and 2
interferons (IFNs), and the B cell–driving cytokines B lymphocyte stimulator (BLyS) and
interleukin (IL) 10. Up regulation of genes induced by interferons is a genetic "signature" of
SLE. However, lupus T and natural killer (NK) cells fail to produce enough IL-2 and
transforming growth factor (TGF) to induce regulatory CD4+ and inhibitory CD8+ T cells.
The result of these abnormalities is sustained production of pathogenic autoantibodies and
immune complexes, which bind to target tissues, with activation of complement and
phagocytic cells that recognize Ig-coated circulating blood cells. Activation of complement
and immune cells leads to release of chemotaxins, cytokines, chemokines, vasoactive
peptides, and destructive enzymes. In the setting of chronic inflammation, accumulation of
growth factors and products of chronic oxidation contribute to irreversible tissue damage in
glomeruli, arteries, lungs, and other tissues.
DIAGNOSIS
The diagnosis of SLE is based on the characteristic clinical features and autoantibodies. In
1971, the American Rheumatism Association (ARA) published preliminary criteria for the
classification of SLE. These criteria were developed for clinical trials and population studies
rather than for diagnostic purposes (48). The 1982 revised criteria, is a simplified and updated
version of the 1971 preliminary criteria that incorporated newer immunologic criteria and
aggregates of some organ system manifestations into single criteria. It consists of 11 items,
compared with 14 in the initial criteria. Because the presence of antiphospholipid antibodies
and the antiphospholipid syndrome (APS) was increasingly recognized in SLE patients, the
Diagnostic and Therapeutic Criteria Committee of the ACR updated the 1982 revised criteria
for SLE in 1997(49).
The 1997 Revised Criteria for the Classification of Systemic Lupus Erythematosus
(SLE)
Criterion Definition
1. Malar rash Fixed malar erythema, flat or raised
2. Discoid rash Erythematous-raised patches with keratic scaling and follicular
plugging; atrophic scarring may occur in older
3. Photosensitivity Skin rash as an unusual reaction to sunlight, by patient history or
physician observation
4. Oral ulcers Oral or nasopharyngeal ulcers, usually painless, observed by physician
5. Arthritis Nonerosive arthritis involving two or more peripheral joints,
characterized by tenderness, swelling, or effusion
6. Serositis a. Pleuritis (convincing history of pleuritic pain or rub heard by
physician or evidence of pleural effusion)
                                                       OR
b. Pericarditis (documented by ECG, rub, or evidence of pericardial
effusion)
7. Renal disorder a. Persistent proteinuria (>0.5 g/d or >3+)
                                                       OR
b. Cellular casts of any type
8. Neurologic
disorder
a. Seizures (in the absence of other causes)
                                                       OR




                                                       OR
b. Leukopenia (<4,000/mL on two or more occasions)
                                                       OR
c. Lymphopenia (<1,500/mL on two or more occasions)
                                                  OR




                                                 OR
b. Anti-Sm
                                                 OR
c. Positive finding of antiphospholipid antibodies based on (1) an
abnormal serum level of IgG or IgM anticardiolipin antibodies, (2) a
positive test result for lupus anticoagulant using a standard method, or
(3) a false-positive serologic test for syphilis known to be positive for
at least 6 months and confirmed by Treponema pallidum
immobilization or fluorescent treponemal antibody absorption test
11. Antinuclear
antibody
An  abnormal  titer  of  antinuclear  antibody  (ANA)  by
immunofluorescence or an equivalent assay at any time and in the
absence of drugs known to be associated with drug-induced lupus
syndrome
Any combination of ?4 of 11 criteria, well documented at any time during an individual's
history, makes it likely that the patient has SLE. (Specificity and sensitivity are 95% and
75%, respectively.)
CARDIOVASCULAR MANIFESTATIONS OF LUPUS
The  heart  is  a  major  target  for  disease  in  patients  with  systemic  lupus
erythematosus (SLE). Several clinical and postmortem studies have demonstrated a high
incidence of cardiovascular manifestations involving the pericardium, myocardium,
endocardium, cardiac valves, and coronary vessels. (50, 51) Although the association of
raised anticardiolipin antibodies with SLE and other lupus like syndromes has been well
described, (52, 53) there is little prospective data on their possible role in the development of
cardiovascular abnormalities (54). There are now a few reports (6,55) describing an
association between valvular lesions and raised anti cardiolipin antibodies in patients with
SLE,  but  the  spectrum  of  cardiac  pathology  and  the  predictive  value  of  high  levels  of  anti
cardiolipin antibodies to the presence of cardiac involvement have not been fully established.
This has been made possible with increased use of two-dimensional echocardiography and
Doppler techniques in the living population with SLE.
PERICARDIAL DISEASE
Pericarditis is the most common form of cardiac involvement in SLE, although
often it is not evident clinically. Its prevalence is also greater in autopsy samples, thus
indicating that asymptomatic pericardial involvement is quite common (57).
Echocardiographic evidence of pericardial thickening or effusion is detected in 18% to 54%
of SLE patients (58, 59), whereas pericardial disease at autopsy has been reported in up to 61
% (57). Evaluating several clinical studies in the literature, Doherty and Siegel (5) found a
25.6% prevalence of pericarditis in 1,194 patients with SLE, but a prevalence of 62.1% in the
254  cases  at  autopsy.  A  great  amount  of  the  pericarditis  may  consist  of  small  effusions  in
asymptomatic patients. Although pericarditis can occur at any time during the course of SLE,
it can even be the first manifestation of lupus.  Coexistent pleurisy or effusions are common,
occurring in 14 of 28 cases in one series (60). Pericarditis usually appears as an isolated
attack or as recurrent episodes, with or without symptoms. In a French series of 28 cases of
pericarditis, 23 had pain, 12 had a rub, and 4 required pericardiocentesis because of
tamponade (60).
 The clinical presentation is usually typical and includes fever, tachycardia,
substernal pain (which worsens during breathing, coughing or leaning forward), and by the
presence of pericardial rub on auscultation. ECG findings in acute pericarditis include PR
segment depression and widespread, upwardly concave ST segment elevation. T-wave
inversions usually occur several days into the clinical course which is not different from that
seen in other causes of pericarditis (61, 62).
 Electrical alternans and reduced QRS voltage are most often seen when large
effusions are present. The inflammation may reach the sinoatrial node or the atrioventricular
node  and  provoke  arrhythmias.  In  one  study,  only  patients  with  moderate  or  severe
pericardial effusion had clinical or ECG evidence of pericarditis (63). Chest radiographs may
reveal an enlarged cardiac silhouette when an effusion is present, and pericardial fat lines
may be visible. When present, pericardial effusions are usually small and do not cause
hemodynamic problems. Pericardial tamponade has been reported but rare. In the modern era,
most pericardial effusions do not cause hemodynamic problems (61). Constrictive pericarditis
is very rare. Pericardial fluid in SLE is usually exudative, the amount of fluid varying from
100 to more than 1,000 ml.
M-mode and two-dimensional echocardiography are currently considered the main
complementary methods used for the diagnosis of pericardial effusion. However, the absence
of pericardial effusion on echocardiography should not exclude the possibility of a clinically
suspected pericarditis. In cases of pericardial constriction, computerized tomography (CT)
and magnetic resonance imaging (MRI) are superior to echocardiography for the
visualization of pericardial thickening and calcifications.
The pericardial fluid of patients with SLE frequently contains lupus erythematosus
cells and low complement levels compared with that found in serum. Antinuclear antibodies,
anti DNA antibodies, and rheumatoid factor may also be found in the pericardial effusion
(61). The eventual finding of antinuclear antibodies is considered virtually pathognomonic of
pericarditis associated with SLE.
 For symptomatic patients with a small  effusion, treatment should include the use
of nonsteroidal anti-inflammatory drugs, such as indomethacin with or without antimalarial
medication. For the more severe cases, or those that do not respond to the above measures,
usually steroids are used in dosages that vary from 0.5-1mg/kg/day of prednisone, according
to the seriousness of the involvement. Pericardial drainage and pericardiectomy rarely need to
be performed.
MYOCARDITIS AND CARDIOMYOPATHY
Myocarditis is the most characteristic feature of myocardial involvement in SLE.
However, in SLE patients myocardial dysfunction may be the consequence of other features,
particularly coronary artery disease (CAD) due to premature atherosclerosis, hypertension,
renal failure, valvular disease and toxicity from medications, such as cyclophosphamide and
chloroquine(3).The recognition of myocardial involvement as a result of SLE has been
considerably enhanced as a result of the hemodynamic and echocardiographic findings of
systolic and diastolic dysfunction, in several patients with lupus who did not show clinical
evidence of heart disease (5,63). Nowadays, clinically overt myocarditis is uncommon and
reported in 7–10% of cases (64), probably as the consequence of the introduction of steroid
therapy. However, as for other cardiac manifestations, subclinical involvement is probably
more frequent. A greater frequency of myocarditis (40% to 80%) is observed on autopsy. The
lower frequency of myocarditis in a series of necropsies more recently studied may be
attributed to the greater use of steroids in patients with SLE (63).
In myocarditis, histological findings show small foci of fibrinoid necrosis with
infiltrates of plasma cells and lymphocytes and small foci of myocardial fibrosis, common in
patients treated with corticosteroids (64). Immunofluorescence studies demonstrate fine
granular immune complexes and complement deposition in the walls and perivascular tissues
of myocardial blood vessels, supporting the hypothesis that lupus myocarditis is an immune
complex-mediated vascular phenomenon (64). Some reports demonstrate an association
between anti-Ro/SSA antibodies and myocarditis (65).
The clinical identification of lupus myocarditis may be more difficult due to the
frequent occurrence in SLE of other factors potentially responsible for myocardial damage,
such as anemia, hypertension, systemic infection, valvular disease, water retention related to
renal disease or the use of steroids. Patients who present with acute myocarditis usually have
associated pericarditis. They also frequently have fever and tachycardia, which may be
disproportionate to fever and thoracic pain. Such patients may only occasionally have signs
of heart failure, arrhythmias, electrical conduction disorder, and intraventricular or
atrioventricular blocks (63).
Thus ventricular dysfunction caused by lupus myocarditis usually is not of a great
magnitude, and therefore the so-called lupus cardiomyopathy is of high intensity rarely with
symptoms and sometimes even without symptoms (66). Cardiac failure may occur
occasionally, mostly in association with severe dilated cardiomyopathy, resulting from
isolated myocarditis, or of several repeated episodes of myocarditis. However, congestive
heart failure, as an independent event, is reported in less than 5% of lupus patients, which
makes it secondary in importance to hypertension, sometimes resulting from use of steroids
(63).
Asymptomatic lupus myocardial dysfunction seems to be a frequent occurrence.
There are several promising noninvasive investigations for diagnosing myocardial
involvement in SLE. Echocardiography shows findings that, although not specific, are
indicative of myocardial inflammation and/or dysfunction such as global, regional or
segmental wall motion abnormalities, decreased ejection fraction, increased chamber size and
prolonged isovolumetric relaxation time. Scintigraphy using gallium citrate 67 or indium
111-labelled  Fab  fragments  of  antimyosin  antibody,  MRI  with  T1  spin  echo  and  T2
relaxation time (67) may be useful in the diagnosis of myocardial inflammation. In general
terms, the electrocardiogram, which can show atrial and ventricular premature beats with
nonspecific  alterations  in  the  ST segment  and  T waves  and  the  chest  X-ray,  which  only  in
cases of severe systolic dysfunction shows enlargement of the cardiac silhouette, have low-
specificity in lupus myocarditis, usually producing results similar to those of other causes of
cardiomyopathy.
An increase in muscle enzymes may be present in patients with lupus carditis,
which is a condition eventually associated with peripheral myositis, where the dosage of total
creatine phosphokinase (CPK) and the muscle - brain fraction of creatine phosphokinase (CK
- MB) in these patients would certainly be useful. The acute lupus myocarditis with serious
clinical and hemodynamic involvement is treated with a high dosage of prednisone
(1mg/kg/day). A minimum 7 - 14 days of treatment is recommended. Diuretics, vasodilators
and digitalis can be used. Immuno-suppression agents, such as azathioprine and
cyclophosphamide have also been occasionally used.
VALVULAR HEART DISEASE
Anatomical and functional valvular abnormalities have been described in SLE.
Libman–Sacks endocarditis, also termed ‘atypical verrucous endocarditis’, is the most
characteristic lesion (4). However, valvular thickening and regurgitation are more frequently
observed than verrucous endocarditis. Anatomical lesions were observed in 15–75% in
necroscopy studies, in 40–50% of cases with the transthoracic echocardiography (TTE) and
in 50–60% with transesophageal echocardiography (TEE). Therefore, TEE is more sensitive
than TTE in revealing valve abnormalities. (68)
Libman - Sacks endocarditis (atypical verrucous endocarditis, noninfectious) is
considered a characteristic, even pathognomonic, finding of SLE. The name refers to
verrucous vegetation, usually ranging in diameter from 1 - 4 mm. This vegetation can be
found isolated or in conglomerates, usually strongly adhered to the endocardium of valve
cusps, but also to chordae tendineae, papillary muscles and the atrial walls or ventricular
endocardium. The four heart valves may be involved, the most common site being the mitral
valve (posterior leaflet), and the second most common site, the aortic valve (5). Microscopic
examination of the lesions shows degenerative cells, fibrin, fibrous tissue and occasionally
hematoxylin corpuscles with a variable degree of inflammation. An association between
valvular abnormalities and antiphospholipid antibodies (aPL) has also been reported, but this
association remains a matter of controversy. Two major pathogenetic hypotheses could
explain the development of valvular abnormalities in SLE patients:  1) aPL and anti-
endothelial antibodies bind to and activate endothelial cells, leading to platelet aggregation
with thrombus formation; and 2) deposition of immune complexes between the endothelium
and the basal membrane, leading to an infiltration of inflammatory cells.
Libman - Sacks endocarditis is primarily an anatomopathological and not a clinical
finding. The lesions in this type of involvement are usually silent, and the occasional clinical
problems associated with them are related more to embolic phenomenon or overlying
valvular dysfunction or heart failure (66). The real prevalence of this type of involvement is
hard to determine during clinical examinations alone, considering the fact that most of the
murmurs heard on auscultation in lupus, which usually result from fever, anemia, tachycardia
and cardiomegaly, are not associated with organic valvular disease.
On the other hand, Libman - Sacks endocarditis is frequently reported on
necropsies of patients who had no indication of murmurs during clinical examination.  The
cardiac vegetations, usually small, are difficult to detect on echocardiogram, although this
method might be useful when the vegetations are larger than 2mm. Vegetations of 10mm in
diameter or larger may be found in some patients with Libman - Sacks endocarditis (5). The
incidence of this type of endocarditis has progressively declined during the last four decades,
because of the use of more efficient therapeutics for SLE in recent years, compared with the
initial period of 1920 and 1930 when the lesions were first described. Corticosteroids’
specific mechanism of action is controversial. Some people attribute the possible reduction in
the incidence of these lesions in lupus to an increase in corticoid use (5), and also a possible
reduction in valvular dysfunction, because they promote healing of scars caused by verrucous
lesions, which would result in fibrotic retraction of valve cusps (63). Another possible
explanation for the lower frequency of verrucous endocarditis described in recent years is that
the diagnosis of SLE is now carried out before death through clinical criteria, and not by the
postmortem finding of cardiac vegetations, as in the past, when the recognition of the high
specificity  of  the  lesions  and  the  absence  of  other  diagnostic  criteria  for  SLE  stimulated  a
search  for  them  on  necropsies  (5).  Although  Libman  -  Sacks  endocarditis  rarely  results  in
considerable hemodynamic involvement, some complications, such as rupture of the chordae
tendineae, aortic stenosis, localized thrombosis and cerebral embolism, are reported.
Infectious endocarditis may complicate Libman - Sacks endocarditis. Doherty and Siegel (5)
demonstrated this in a meta-analysis of 15 reports showing that 4.9% of cases of verrucous
endocarditis identified at necropsy and 33% of cases clinically diagnosed had infectious
endocarditis as a complication. Such frequencies are greater than in the general population or
even in patients with other diseases of the connective tissue. Therefore, the prophylactic use
of antibiotics in dental and surgical procedures is indicated in patients with Libman - Sacks
endocarditis (63).
Valvular thickening, whether or not due to Libman – Sacks endocarditis, visualized
with M-mode or two dimensional echocardiography may be observed in about half of
patients with SLE. Valvular thickening predominantly occurs in the mitral and aortic valves
(8), and may, in some cases, be correlated with surgical findings of verrucous endocarditis
(63). The most common valvular dysfunction in lupus is regurgitation, which in most cases is
of small magnitude with no clinical significance. However, valvular malfunction, with
considerable clinical and hemodynamic importance to an extent where they require surgical
replacement by prosthesis may occur in certain patients. Aortic regurgitation, which may
result from Libman - Sacks endocarditis, valvulitis, fibrosis, mucous degeneration, bacterial
endocarditis and aortic dissection, is considered to be the valve dysfunction usually
associated with severe hemodynamic importance in SLE (5).
Severe cases of mitral regurgitation have also been reported, however less
frequently. Mitral regurgitation may be caused by fibrosis, thickening and calcification of the
mitral leaf and chordae tendineae, rupture of the chordae tendineae, and fibrinoid necrosis of
papillary muscles. Cases of aortic stenosis, mitral stenosis, and tricuspid stenosis resulting
from in situ thrombosis, some requiring valve replacement, have also been described,
however in limited numbers (5, 8). The valvular evaluation in lupus includes the conventional
findings of clinical examination and electrocardiogram, chest X-ray and echocardiogram. The
transthoracic echocardiography is presently the method most used for diagnosis of valvular
disease associated with SLE. The transesophageal echocardiogram is also beginning to be
used in studies for evaluation of the frequency of valvular involvement in lupus (8). Roldan
et al (8) found a 74% frequency of valvular involvement in SLE using this method. A greater
frequency of regurgitation in the right chambers in relation to the left chambers, as identified
in patients with SLE through Doppler echocardiography, has been associated with pulmonary
vascular lesions, resulting in pulmonary hypertension.
Jansen-Urstad et al (69) recently reported a close association between valvular
abnormalities and cardiovascular disease (CVD) as well as raised levels of homocysteine and
triglycerides in SLE patients. Therefore, patients with valvular disease should be screened for
clinical and subclinical atherosclerotic features.
Since Libman–Sacks endocarditis is clinically silent in the majority of cases, it is
generally not treated. When it is found in an early active stage, corticosteroids (prednisone 1
mg/kg/day) are recommended, especially if antiphospholipid antibodies and lupus
anticoagulant are negative. Valvular abnormalities frequently resolved over time (62).
When endocarditis is detected at a later stage during the course of the disease,
careful clinical surveillance is necessary and, if the lesion becomes hemodynamically
significant, valve surgery is needed. It is necessary to carefully evaluate the type of surgical
treatment. Mechanical valve replacement seems to be the best choice in lupus patients (70).
RHYTHM AND CONDUCTION TISSUE ABNORMALITIES
Sinus tachycardia is the most frequent rhythm abnormality and is quite common in
SLE patients. Atrioventricular block and bundle branch block are also observed. However,
they are rare in adults (71) and occur in only 2% of children born from mothers with anti-
Ro/SSA antibodies (72). Rhythm and conduction abnormalities are mostly asymptomatic or
may lead to some mild complaints such as palpitation or fatigue. In some cases syncope may
occur. Sinus tachycardia can be due to fever, anaemia or cardiac abnormalities including
pericarditis  and  myocarditis.  Conduction  defects  can  also  be  the  result  of  anti  malarial  use
(71). In SLE patients with rhythm and conduction abnormalities, electrolyte balance and
thyroid hormonal status should be investigated. The treatment is based on the use of common
anti arrhythmic drugs and in the most severe cases the implant of a pacemaker is necessary.
PULMONARY HYPERTENSION
Association of pulmonary hypertension with diseases of the connective tissues has
been most frequently described in the combination of connective tissue disease and systemic
sclerosis, this last especially in CREST syndrome (calcinosis, Raynaud’s phenomenon,
sclerodactyly, esophageal involvement and telangiectasia). Although acute pulmonary arterial
hypertension continues to be considered a rare manifestation, it has been demonstrated to be
common in patients with subclinical or mild cases of SLE, and a current trend exists to
recognize pulmonary arterial hypertension as a complication of SLE (63). The determination
of the real prevalence and magnitude of pulmonary hypertension in SLE has been difficult
over the years due to the fact that the only method with sufficient sensitivity for determining
pulmonary pressures and confirming the existence of pulmonary hypertension has been the
catheterization of the right chambers with direct measurement of pulmonary pressures (73),
an invasive method that one is naturally reluctant to use before symptoms and signs of
advanced disease are present. In fact, in older reports a trend can be observed of studying
patients with SLE with well defined clinical manifestation of pulmonary arterial hypertension
(74), which usually is associated with high pressure levels in the pulmonary artery.
The advent of two-dimensional Doppler echocardiography, a method thought to be
of similar sensitivity as right chamber catheterization for measuring pulmonary pressure,
allowed the study of a greater number of patients, with or without symptoms. Simonson et al
(73), by way of Doppler echocardiography, found a frequency of pulmonary artery
hypertension (defined as systolic arterial pressure >30mmHg) of 14% in 36 patients with
SLE, observing in these patients a slight increase pulmonary pressures, suggesting that
pulmonary arterial hypertension in SLE is common, although of light intensity. A gradually
progressive pulmonary hypertension in lupus was demonstrated by Winslow et al (75), when
reevaluating this same group of patients five years later and concluding that the prevalence of
pulmonary hypertension increased from 14% to 43%. The real causes of pulmonary
hypertension in SLE are yet unknown. The hypothesis of pulmonary vasculitis, with deposits
of immune complexes and complements on the pulmonary artery walls, thromboembolic
blockage in pulmonary vessels, possibly related to antibodies, and vasospasms, are suggested
by a greater frequency of Raynaud’s phenomenon in these patients (63, 73).
In lupus, the rare forms of pulmonary arterial hypertension produce symptoms that
usually develop insidiously and gradually progress. Dry cough, thoracic pain and shortness of
breath are usually the first symptoms, which may not be noticed because the physical
examination and chest X-ray are frequently normal during the initial phase. Later, the second
heart sound in the pulmonary area intensifies, and X-ray of the thorax shows an enlargement
of the pulmonary vessels. The electrocardiogram shows overload of the right chambers. At
this point, the Doppler echocardiography or catheterization of the right chamber clearly
shows pulmonary hypertension.
The prognosis for the acute form of the disease is somber. More than 50% of the
patients die within a period of two years. A large number of the patients reported here have
undergone treatment with vasodilators, anticoagulants, corticoids and cytotoxic agents, and in
spite of several reports of improvement of the symptoms, the hemodynamic response has
generally been unsatisfactory. Supportive therapy with oxygen supplementation, diuretics and
anticoagulation is indicated for those with cardiac failure. The joint heart-lung or lung only
transplant has been carried out with success in some patients.
ANTIPHOSPHOLIPID ANTIBODIES (APLS) AND THE HEART IN LUPUS
Antiphospholipid antibodies (aPLs) are most commonly identified through
coagulation tests. They have been associated with thrombotic manifestations, low platelet
counts and miscarriages as frequently in patients with SLE as in a variety of situations, such
as connective tissue diseases, patients with neoplasia, acquired immunodeficiency syndrome,
the use of certain drugs (phenytoin, interferon, quinidine, cocaine) or even with no
identifiable illness (76). aPLs were identified in 1952 when Conley and Hartman discovered a
coagulation inhibitor in lupus patients, named lupus anticoagulant (LAC) . Later on it was
discovered that the coagulation inhibitor came from the immunoglobulins IgA, or IgM, or
perhaps both of these directed against the natural phospholipids in the coagulation cascade,
and also that the hemorrhagic disturbances were not frequent. In fact a paradoxical increase
in thrombosis in patients with LAC occurred, by mechanisms not yet well explained, but
whichmay include a lesion of the endothelium by aPLs (77). On the other hand, it was also
observed that the LAC was frequently associated with the presence of false-positive serum
tests for syphilis, which also commonly occurs in lupus patients.
Based on this observation cardiolipin, a phospholipid originally extracted from
bovine hearts and used for serum tests for syphilis, was introduced as an antigen in solid
phase immunology studies, such as radioimmunoassay and enzyme-linked immunosorbent
assay  (ELISA)  .  Presently,  ELISA  is  the  most  commonly  used  method  for  the  research  on
aPLs and for the detection of anticardiolipin antibodies (aCL) of the IgM, IgG, or IgA type,
or all of these.
 A spectrum of cardiac involvement has been reported in several types of patients
with  aPLs,  which  suggests  the  possibility  of  aPLs  also  being  responsible  for  the  basic
immunological  events  related  to  the  onset  of  heart  disease,  and  that  certain  cardiac
manifestations may, in fact, be part of the primary or secondary so-called antiphospholipid
antibody syndrome (aPL syndrome) defined as a set of clinical manifestations associated with
the presence of these antibodies (78). Although some authors have not found any association
between cardiac manifestation in lupus and the presence of aPLs (8, 79) other authors
demonstrate a significant frequency of aPLs in lupus patients with different forms of
cardiomyopathy. Among cardiac manifestations of SLE Libman - Sacks endocarditis and
especially valvular defects and valvular thickening are the most frequently reported as being
associated with aPLs (6, 7, 80). These findings have been reinforced by the fact that valvular
lesions similar to those found in lupus have been found in patients with primary aPL
syndrome (78). Whether the aPLs are the cause of valvular lesions, or simple coincidence
accompanied by other immunological disorders, is not known. The findings of selective
immunoglobulin deposits and complements along with cardiac vegetations in patients with
Libman - Sacks endocarditis, suggesting involvement of a part of the immune complexes in
the onset and growth of the lesions (78), should be emphasized, however, as should the more
recent and suggestive findings of anticardiolipin antibody deposits in the sub endothelial
layer of valves in patients with aPL syndrome.
Several cases of myocardial infarction have been documented in patients with
primary aPL syndrome or aPL associated with lupus. The antiphospholipid antibodies may in
this way become additional risk factors for coronary disease in patients with SLE, in addition
to arteritis and classic accelerated atherosclerosis (78). The observation that antibodies
against low density lipoproteins (LDL), which are also considered antiphospholipid
antibodies due to the presence of phospholipids and apolipoprotein B in the LDL molecules
have been found to be more clearly associated with atherosclerotic phenomenon than with the
thrombotic phenomenon itself, which suggests the interesting possibility of aPLs being
directly responsible for the development of atherosclerosis in patients with SLE (81).  Some
evidence of the possible relation between the aPLs and myocardial infarction is also reported
in studies of patients who do not have SLE or aPL syndrome. Hamsten et al (82) evaluated
62 survivors of a first myocardial infarction, less than 45 years old, and found high levels of
anticardiolipin (aCL) in 13 (21%). Eight of the 13 patients with aCL levels persistently high
experienced additional cardiovascular events during a 36 - 64 month follow-up, which
suggests that aCL should be interpreted as a risk factor for recurrent cardiovascular events
after the first myocardial infarction.
Zuckerman et al (83) evaluated 124 non lupus patients less than 65 years old who
survived an acute myocardial infarction, and similarly observed that the incidence of
thromboembolic events and re-infarction during a variable follow-up period of 12 to 27
months was significantly higher in patients positive for anticardiolipin antibodies.
Pulmonary hypertension in SLE has also been associated with the presence of
aPLs. Asherson et al. (84) found a frequency of aPLs of 68% in 24 patients with pulmonary
hypertension,  22  of  these  with  SLE,  one  with  primary  aPL  and  one  with  overlying
SLE/sclerodermatitis syndrome.
Leung  et  al (61) evaluated 75 patients with SLE by Doppler echocardiography,
ELISA for aCL and various tests for LA and concluded that of five patients with myocardial
dysfunction, four (80%) were positive for aPLs (p<0.05). Thrombotic closures of the
myocardial microcirculation, in the absence of vasculitis (cardiac microangiopathy), may be a
possible explanation for this type of anomaly in patients with aPLs (78).
Other cardiac manifestations in lupus, such as pseudo infectious endocarditis -
which is a type of acute thrombosis of Libman - Sacks endocarditis, related to periods of
activity of SLE with clinical findings quite similar to those of bacterial endocarditis - and the
intra  cavity  thrombus,  have  also  been  associated  with  the  presence  of  aPLs  (78),  which
correlates with a greater frequency of cerebral, ischemic events found in patients with aPLs.
ACCELERATED ATHEROSCLEROSIS
Atherosclerosis is emerging as a significant cause of death and illness in patients
with systemic lupus erythematosus. The mortality rate from coronary artery disease in
patients with systemic lupus erythematosus is estimated to be nine fold greater than predicted
population-based rates (85). Severe atherosclerotic narrowing of coronary arteries has been
well documented on autopsy studies, even in patients younger than 35 years of age.
Although the pathogenesis of accelerated atherosclerosis is unknown, it is believed
to be multifactorial. Traditional cardiac risk factors, such as hypertension, obesity, and
hyperlipidemia, are observed with high frequency in patients with systemic lupus
erythematosus. Fifty-three percent of these patients have three or more risk factors; this
prevalence greatly exceeds the prevalence seen in a matched population (6). Glucocorticoid-
induced dyslipoproteinemia (86) and complications that result from disease involvement in
other organ systems (for example, renal disease leading to hypertension and hyperlipidemia)
may also potentiate the atherosclerotic process. Circulating immune complexes may promote
intracellular cholesterol accumulation and therefore may be an additional compounding factor
(87).
Risk factors for atherosclerosis in SLE
In SLE patients the role of traditional and nontraditional risk factors for
atherosclerosis  is  still  debated.  Patients  with  SLE  have  abnormalities  in  their  lipid  profile.
Corticosteroid therapy has been implicated in the development of vascular disease in SLE
patients  (88).  Patients  with  more  active,  severe  SLE  will  receive  higher  doses  of
corticosteroid therapy for a longer time, although the relationship between corticosteroids and
vascular  disease  in  SLE  patients  remains  controversial.  Most  ultrasound  studies  in  SLE
patients have found an association between carotid plaque and corticosteroid therapy.
Moreover, corticosteroid therapy seems to increase the serum concentration of lipoproteins,
(9) whereas hydroxychloroquine seems to reduce them in SLE patients.  Other studies (9, 89)
have shown an important role of hypertension, sedentary lifestyle and hyperhomocysteinemia
in the development of atherosclerosis. Corticosteroids and nephropathy could lead to an
increase of homocysteine.
Among the SLE-related risk factors, besides cumulative dosage (89) and/or length
of corticosteroid therapy, (9) disease duration, high scores of activity (measured by scoring
systems such as SLAM, SLEDAI or ECLAM) or damage (SLICC DI), (90) could contribute
to  the  development  of  atherosclerotic  plaque.  However,  it  is  not  yet  clear  whether  patients
with mild or with severe disease are more at risk.
More recently, some novel risk factors for atherosclerosis have been proposed and
reviewed (91). They are inflammatory markers (CRP and other pentraxines), immunological
factors (anti-b2 glycoprotein I, antioxidized LDL, anti-heat shock protein 60/65), lipoproteins
or coagulation parameters which are abnormal in SLE patients due to the disease itself.
Therefore SLE is an intriguing model from this point of view. Unfortunately, data on the role
of novel predictors in SLE cohorts are limited.
CAROTID IMT IN SLE
Noninvasive imaging techniques have been used to explore why SLE predisposes
women  to  excess  CVD  risk. Both carotid IMT and plaque can be measured using B-mode
ultrasound in women with SLE. Using these modalities, studies have shown increased rates
of carotid focal plaque in women with SLE compared with controls.
Manzi S et al (92) studied a group of 175 women with SLE [predominantly white
(87%)] with a mean age of 44.9 years  and  found that older age, elevated pulse pressure, a
previous coronary event, and a higher SLICC disease damage score were independently
related to increased IMT (P < 0.05). Independent determinants of plaque (P < 0.05) were
older age, higher systolic blood pressure, higher levels of LDL cholesterol, prolonged
treatment with prednisone, and a previous coronary event. Older age, a previous coronary
event, and elevated systolic blood pressure were independently associated with increased
severity of plaque (P < 0.01).
Roman MJ et al (93) in his study of 197 SLE patients and equal number of
controls noted that the risk factors for cardiovascular disease were similar among patients and
controls. Carotid plaque was more prevalent among patients than controls (37.1 percent vs.
15.2 percent, P<0.001). But the mean carotid IMT was comparatively lower in the patient
group. Independent predictors of plaque were a longer duration of disease, a higher damage
index score, a lower incidence of the use of cyclophosphamide, and the absence of anti-Smith
antibodies.
S.  Jime´nez  et  al. (94) found that SLE  patients  had  a  higher  prevalence  of
traditional atherosclerosis risk factors: hypertension and dyslipidaemia and higher levels of
total  cholesterol,  triglycerides  and  apolipoprotein.  The  prevalence  of  carotid  plaque  was
higher and appeared earlier in SLE patients than in the primary APS patients or controls. The
IMT was similar in the three groups. Plaque prevalence in patients with primary APS (8%)
was similar to that of controls (15%) and inferior to that of SLE patients with secondary APS
(28.6%). SLE patients had a high prevalence of early carotid atherosclerosis that was
associated with cumulative disease damage and disease activity and older age at the time of
study (47.3±8.44 yrs vs 37.38±11.28 yrs, P<0.003) and found no correlation between IMT
and the different antiphospholipid antibodies (aPL) or their titers. But in another study, in
patients with primary APS, the IMT correlated with the anticardiolipin antibody titer and was
greater in thrombotic than in non-thrombotic subjects.
Trina Thompson et al (95) noted that in the lupus patients, the frequency of
plaque progression was higher (27% versus 10%) and the degree of IMT progression was
similar (0.011 mm/year versus 0.008 mm/year) compared with those in a control group. The
prevalence  of  carotid  plaque  was  found  in  31%  of  SLE  patients,  similar  to  that  in  women
with SLE.
Bhatt SP et al (96) compared 50 patients with SLE with 50 age- and sex-matched
healthy control subjects. Patients with lupus (mean ± SD age 31.6 ± 10.05 years, median age
30.5 years; mean±  SD disease duration 52.3 ± 36.7 months, median disease duration 46
months) exhibited significantly greater intima-media thickness (IMT) than controls (mean ±
SD 0.417 ± 0.07 mm versus 0.362 ± 00.07 mm; P < 0.003). Carotid plaques were seen in 7
patients (14%). None of the control population had plaques (P< 0.006). The  IMT  was
significantly associated with age, systolic blood pressure (SBP), disease duration and
menopausal status in this study.
Carotid ultrasonography has consistently showed more atherosclerotic plaques in
SLE patients than in matched controls, but measurement of the intima-medial thickness,
which is also indicative of subclinical atherosclerosis, has yielded conflicting results.  The
conflicting results for IMT in different studies, as mentioned by Westerweel et al (97), could
be attributable to varying criteria used to select control groups. For example, Manzi et al (92)
included as a control group, women participating in a lifestyle project at their institution.
These women were older (mean age 49.0 years) compared with lupus patients (mean age 44.9
years). Also, the patient and control groups were not matched for menopausal status, race, or
other cardiovascular risk factors. Similarly, the control population in the study by Roman
MJ et al (93) included both normotensive and hypertensive patients, and the control subjects
had significantly higher blood pressure than the patients,  at  the time of study. Both age and
hypertension influence IMT and could have accounted for an increase in IMT of the control
population in the aforementioned studies, thereby blunting the difference in IMT between
control subjects and patients with lupus. Asian Indian patients with lupus, despite being
relatively young and having shorter disease duration, exhibited premature atherosclerosis in
the form of significantly thicker intima-media and plaque (96).
STUDIES FROM INDIA
Most studies from India reported the overall clinical/immunological profile of
SLE. There are only a limited number studies on cardiovascular manifestations reported from
India. The prevalence of cardiac involvement was from 5.3% to 58.5%.  Surjit Singh et al
(98) in their retrospective analysis, found 18.7 % patients to have cardiac involvement among
the  16  children  with  SLE  analysed.  Cardiovascular  involvement  was  seen  in  the  form  of
pericarditis, myocarditis, endocarditis and right heart failure. One child had severe
myocarditis and another had large pedunculated (1 cm x 0.7 cm) vegetation on the mitral
valve without any valvular compromise. The study from south India (A N Chandrasekaran
et al) (99) noted 10.2% cardiac involvement in childhood SLE. Another study from Madras
found 28% cardiac involvement among 330 SLE patients (100).
Cardiac involvement was seen in 5.3% of patients with SLE, in a study from
Northern Kerala (101). Two had pericardial effusion and two had mitral regurgitation. One
patient had an isolated right bundle branch block.
S Kalke et al (59) in his case control study, performed echo for 54 patients with
SLE and 20 age, sex matched controls, whom nine (17%) had significant cardiac involvement
(four left ventricular hypertrophy, one moderate pericardial effusion, one severe aortic
regurgitation, and three ventricular systolic dysfunction). Anticardiolipin antibodies (both IgG
and IgM) were elevated in five patients (13 studied). One of them had severe mitral
regurgitation, one had trace mitral and aortic regurgitation and one had diastolic dysfunction.
There was no linear correlation between disease activity and diastolic dysfunction.
An autopsy study of 27 SLE patients from India (103) noted that the valvular
lesions were the commonest cardiac lesions noted with non-bacterial thrombotic endocarditis
in nine (33.33%), valvular thickening in two (7.41%), Libman-Sacks endocarditis and
infective endocarditis in one (3.70%) each. Myocarditis and myocardial scarring were seen in
10 (37.03%) and seven (25.92%) cases, respectively. Fibrinous pericarditis was noted in
seven (25.92%). Thrombosis/ embolism, vasculitis and severe coronary atherosclerosis were
seen in nine (33.33%), five (18.52%) and one (3.70%) subjects, respectively. Renal disease
[48.14%] and cardiovascular manifestations [29.62%] were the leading causes of mortality.
 In a recent cross sectional study (104), 58.5% patients had some form of
cardiovascular abnormality detected by either ECG or Echo. There  were  78  females  and  4
males (F: M=19.5:1) with mean age of 28.4 ± 9 years. Echo abnormality was detected in
38/82 patients (46%) that ranged from pericardial effusion in 20 patients (24%), mitral
regurgitation in 10 (12%), tricuspid regurgitation in five (9%) and mitral valve prolapse in 2
(2%). Dilated cardiomyopathy was detected in seven patients (8%). Diastolic dysfunction
was detected in eight patients (10%) and pulmonary artery hypertension was noted in three
patients (4%). ECG abnormality was detected in 31 patients (38%). This comprised of sinus
tachycardia  in  22  (26%),  LVH in  three  (4%),  non-specific  ST-T changes  in  three  (4%)  and
low voltage complex in three patients (4%). They did not find any relationship between
cardiovascular status of SLE patients and disease duration, steroid dose or disease activity
(SLEDAI scores).
AIM
AIM OF THE STUDY
1) To identify the various cardiac manifestations in patients with systemic lupus
erythematosus.
2) To detect the risk of association of anti cardiolipin antibodies and lupus anticoagulant
with cardiac involvement in lupus patients.
3) To determine the correlation between the risk factors for atherosclerosis  and carotid





In this prospective study, 100 consecutive patients (95 females, 5 males) with
systemic lupus erythematosus (who fulfilled the1997 revision of ACR 1982 classification
criteria for classification of systemic lupus erythematosus) attending the rheumatology
outpatient clinic or as inpatients in the rheumatology ward of Government General Hospital,
Chennai constituted the study group. This study was done during March 2007- March 2009.
Inclusion criteria
Patients who fulfilled the 1997 revision of ACR 1982 classification criteria for systemic
lupus erythematosus were included.
Exclusion criteria:
Patients with overlap syndrome
Preexisting cardiac illness due to other causes.
Patients with renal failure (defined by a serum creatinine level of 3.0 mg/dl [265moles/liter]
or acreatinine clearance of 30 ml/minute).
Apart  from  age  and  sex, detailed history including mode of onset, duration of
illness, constitutional, mucocutaneous, musculoskeletal and symptoms pertaining to the
cardiovascular system i.e. chest pain, palpitation, breathlessness, leg swelling and relevant
history of other organ involvement was obtained. History of recurrent abortion if relevant,
venous or arterial thrombosis and dose of steroid therapy at the time of study were noted. All
patients were questioned for history of rheumatic fever, infective endocarditis, hypertension,
diabetes, alcohol and smoking habits.
Clinical examination included general examination, pulse rate, blood pressure,
detailed cardiovascular system, musculoskeletal and other organ system examination done in
all patients.  Patients were considered to be hypertensive when they had systolic BP? 140 mm
Hg and/or diastolic BP ?90 mm Hg (The JNC 7 Report. JAMA 289:2560, 2003) and/or when
they were taking antihypertensive drugs.
Laboratory investigations including complete haemogram, urine analysis including
microscopic examination and urine PCR were noted. Biochemical parameters including
blood glucose, urea, serum creatinine, serum electrolytes, liver function tests and fasting lipid
profile were done for all patients.
Hypercholesterolemia is defined as Total Cholesterol >200mg/dl, LDL-
Cholesterol as >130mg/dl, hypertriglyceridemia as TGL >150mg/dl and HDL- Cholesterol
<40mg/dl. Dyslipidemia is defined as presence of one or more than one abnormal serum lipid
concentration (third report of the National Cholesterol Education Program (NCEP)
expert panel on detection, evaluation, and treatment of high blood cholesterol in adults
(adult treatment panel III). JAMA 285:2486, 2001, Implications of recent clinical trials
for the National Cholesterol Education Program Adult Treatment Panel III Guidelines:
SM Grundy et al for the Coordinating Committee of the National Cholesterol Education
Program. Circulation 110:227, 2004). Persons with fasting blood glucose >126mg/dl or
symptoms of hyperglycemia and a casual plasma glucose ?200 mg/dl or 2-hr plasma glucose
?200 mg/dl (11.1 mmol/l) during an OGTT or who were on medication for diabetes was
considered as having diabetes mellitus.
Immunological investigations:
C - reactive protein was done by latex agglutination method, a value >6mg/L taken
as positive. ANA and anti- ds DNA were done by ELISA method (Enzyme Immunoassay
Kit, Binding Site, U.K.).  Anti-Sm antibodies were detected by ELISA method by using
Varelisa kit for the semi quantitative and qualitative determination of anti-Sm D antibodies in
human serum or plasma. aCL IgG and IgM by ELISA was done by using commercial ELISA
kit (CAL BIOTECH, INC).
Principle
Microwells are pre-coated with purified antigen/antigens. The pre-diluted controls,
together with diluted patient samples, are added to the wells, autoantibodies recognizing one
or a combination of antigens bind during the first incubation. After washing the wells to
remove all unbound proteins,peroxidase labeled rabbit anti-human IgG (? chain specific)
conjugate is added. The conjugate binds to the captured human autoantibody and the excess
unbound conjugate is removed by a further wash step. The bound conjugate is visualized with
3,3’,5,5’ tetramethylbenzidine (TMB) substrate which gives a blue reaction product, the
intensity of which is proportional to the concentration of autoantibody in the sample. Acid is
added to each well to stop the reaction. This produces a yellow end point colour, which is
read at 450nm by using ELISA reader.




Cut-off value for anti ds-DNA
Interpretation
<30 IU/mL Negative result
30-75 IU/mL Borderline
>75 IU/mL Positive result
Interpretation of results for anti-Sm antibodies
Assessment Semi quantitative evaluation Qualitative evaluation
Negative <10 U/ml Ratio < 1.0
Equivocal 10-15U/ml Ratio 1.0-1.4
Positive >15 U/ml Ratio >1.4
Interpretation of results for aCL IgG and IgM antibodies
 aCL IgG  aCL IgM
<10 GPL units/ml Negative <15 MPL units/ml Negative





Moderate Positive >20-80 MPL
units/ml
Moderate Positive
>80 GPL units/ml     High positive >80 MPL units/ml      High positive
The complement levels were measured using Single Radial Immune Diffusion
plates. The procedure consists of immunoprecipitation in agarose gel between an antigen and
its homologous antibody. It is performed by incorporating the anti C3 and anti C4 antibodies
uniformly throughout a layer of agarose gel and antigen is added into the wells duly punched
in the gel.  Antigen diffuses radially out of the well into the surrounding gel and a visible ring
of sharp precipitation forms where the antigen and antibody reacted in the zone of
equivalence. A quantitative relationship does exist between ring diameters and complement
concentration. The reference value for C3 is 80-160mg/dl and for C4 is 20-40mg/dl.  Lupus
Anticoagulant Study including activated partial prothrombin time, dilute Russel viper venom
test and Kaolin clotting time were done.
Cardiac evaluation
A standard 12-lead electrocardiogram and chest x-ray were taken on each patient.
The echocardiograms were recorded in all selected patients. Two dimensional, continuous
wave (CW), pulse wave (PW) and color flow Doppler examinations were performed in
parasternal and apical views for structural and hemodynamic findings and valvular function.
Left ventricular systolic function was determined by measuring the ejection fraction (EF) and
fractional shortening (FS) from standard parasternal long-axis view by M-mode
echocardiogram. Diastolic function of left ventricle was evaluated by measuring peak early
diastolic filling velocity (E), peak late diastolic filling velocity (A), E/A ratio (a measure of
relative blood volume, filling the left ventricle in early versus late diastole), isovolumetric
relaxation  time (IRT)  (the  time between aortic  valve  closure  and  mitral  valve  opening)  and
deceleration time (DT) (time between peak E to zero point of velocity) by PW Doppler
echocardiogram. Valvular function was assessed by CW and color flow Doppler
echocardiography. Pulmonary artery systolic pressure was calculated from the peak velocity
of the tricuspid regurgitation jet and estimated central venous pressure. Pulmonary
hypertension was defined as pulmonary artery systolic pressure >30 mm Hg.
Echocardiographic studies were performed with Philips iE33 ultrasound system.
Duplex ultrasonography
Carotid arteries were evaluated using the ALOKA P3500 machine   equipped with
a linear probe (3.5–15 MHz).The intima-media thickness (IMT) was measured at common
carotid artery (10 mm before the bulb), bulb(5–10 mm cranially to the start of the bulb) on
each side. Mean IMT calculated from four values for patients (n=70) and controls (n=20).
The vessels were imaged using multiple planes, and searched for focal plaques. Plaque was
defined as a distinct area of hyperechogenicity and/or focal protrusion of the vessel wall into
the lumen.
Disease activity was assessed in the study with the use of the Systemic Lupus
Erythematosus Disease Activity Index.
Statistical Analysis
The statistical analysis was performed using the SPSS (version 17.0). Results are
presented as the mean ± SD, except for frequencies, which are expressed as percentages.
Comparisons between groups were made by means of 2-sample t-test, and chi square test
used when appropriate. Binary logistic regression analysis was used to predict the possibility
of  having  an  overall  cardiac  disease  and  valvular  heart  disease  from the  predictor  variables
like blood pressure, CRP, LDL, TGL, HDL, Complements, LAC, aCL and from a history of
recurrent abortion in patients with lupus. Pearson correlation was used to identify significant




There were 95 females and 5 males in the study group (Fig 1). The age of the
patients varied from 11 years to 45 yrs (Fig 2). The mean age of the patients was 23±6.77
years. Disease onset in the second or third decade was common (mean age 20.83± 6.29
years).  Almost one quarter of patients had childhood onset of the disease (Fig 3). The mean
disease duration was 2.5±2 years.
Table 1





?3 yrs 40 54.79% 33 45.20% 73
>3 yrs 18 66.66% 9 33.33% 27
Total 58 42 100
?2 = 1.14; ns
The results of the chi square test (Table 1) implied that cardiac involvement is independent of
disease duration in SLE patients.
Symptoms like dyspnea on exertion (27 %), chest pain (15%), palpitation (21%)
and leg swelling (19%) were present. Hypertension and tachycardia were present   in 15%.
Cardiac failure was present in 4% of patients. Pulsus paradoxus due to cardiac tamponade
was seen in one patient, for which pericardiocentesis was done. Systolic thrill in the mitral
area was present in one patient. On auscultation muffled heart sound was present in5%, loud
P2 in 7%, third heart sound in 15%, fourth heart sound in 4%, mid systolic click in the mitral
area in 5%, pan systolic murmur in the mitral area in 4% and pericardial rub was heard in 3%
of patients. 40% of patients with cardiac involvement (by echo) did not have any symptoms
or signs related to cardiovascular system.
           FIGURE 1
              FIGURE 2
FIGURE 3
FIGURE 4
Cardiac abnormalities were found in 42% of patients. 58% patients had no cardiac
involvement. The electrocardiogram (ECG) was abnormal in 25% of cases. The abnormal
findings were sinus tachycardia in 16%, ST-T changes in 5%, conduction abnormalities in 3
% of cases (AVNRT, RBBB and complete heart  block in 1 patient each),  RVH pattern and
low voltage complexes were present in each of 1% of patients. In the chest X-ray PA view,
unilateral & bilateral pleural effusion each was present in 5 % cases. Cardiomegaly was noted
in 7% of patients and pneumonitis in 2%.
Echocardiographic abnormalities were found in 41% of patients (Fig 4). Out of 100
patients, mild pericardial effusion was present in 15%, moderate in 3% and large effusions in
4% of cases. One patient had large pericardial effusion with tamponade and pericardial
strands were noted in another one. Global hypokinesia due to myocarditis was found in 3%.
LV diastolic and systolic dysfunction was found in 6% and 3% of cases respectively. 2% of
patients had mild to moderate concentric LVH.
Valvular abnormalities were seen in 19% of our patients, comprising mitral valve
involvement in (15%), followed by tricuspid in (9%) and then aortic valve in (3%) (Fig. 5).
Mild, moderate, severe mitral regurgitation, mild tricuspid regurgitation and aortic
regurgitation was found in10%, 2%, 1%, 7%, and 3% of cases respectively. Mitral valve
thickening in 1% and mitral valve prolapse was noted in 5% of cases. None had stenotic
valvular lesions. Pulmonary hypertension was seen in 9% of patients (mild- 4, moderate - 3,
severe - 2).
Mucocutaneous and musculo skeletal manifestations were common among the
clinical features noted in the study group.  Recurrent abortion was noted in 4%, digital
gangrene in 5% and deep venous thrombosis of left leg in 1%. None of the patients had




Echo - Pericardial effusion
FIGURE 7
Echo – thickening of the mid portion of the posterior mitral valve leaflet (arrow)
FIGURE 8
Echo – Mitral regurgitation
FIGURE 9
    Echo – Dilated cardiomyopathy
On laboratory investigations, majority of patients (65%) were anaemic (<10 gm),
thrombocytopenia in 15%, elevated ESR in 59% and positive CRP was present in 38% of
patients. Dyslipidaemia was present in half of the patients (54%). Elevated total cholesterol in
44%, hypertriglyceridaemia in 54%, increased low density lipoproteins in 35% and low high-
density lipoprotein (HDL) levels in 21% were noted.
ANA was positive in 97%, anti dsDNA in 71% and Sm antibodies in 34% of cases.
LAC  and  anticardiolipin  antibodies  were  present  in  8%  and  52%  of  cases  respectively.
Reduced complements C3 in39% and C4 were found in 27% of cases. Overall the disease
activity was high (mean±SD = 18.21±10.64). All patients were on steroid therapy. The mean
steroid dose was 16.12 ± 7.25 mg.
Table 2
Comparison of demographic and clinical parameters -


















22.79±6.21 23.48±6.71 0.523 NS








3 7.14% 1 1.72% 1.365 NS
5 Digital
gangrene/DVT





/min (no. of pts)
7 16.66% 8 13.79% 0.397 NS
7 hypertension(no.
of pts)
9 21.42% 6 10.34% 1.352 NS
The analysis in the Tables 2 & 3 show that there exists no statistically significant
difference   between SLE patients with cardiac Vs without cardiac involvement in
demographic, clinical and laboratory parameters, SLEDAI was also included.
Table 3












































3 ESR in mm/1
hr(mean ±SD)
66.95±31.82 66.03±41.75
4 ESR  > 50


































































































Comparison of demographic and clinical parameters –















1 Age in yrs
(mean ±SD)
24.16±5.69 23.48±6.71 0.397 NS








3 15.78% 1 1.72% 2.398 <0.02*
5 Digital
gangrene/DVT
1 5.26% 3 5.17% 0.015 NS
6 Heart rate/min
(mean ±SD)




2 10.52% 8 13.79% 0.368 NS
7  Hypertension
(no. of pts)
4 21.05% 6 10.34% 1.205 NS
* Significant (<0.05)
In Tables 4 & 5 - Comparison of demographic, clinical parameters and SLEDAI
between SLE patients with valvular heart disease Vs without cardiac involvement show that
recurrent abortions were significantly higher in the former group and also the LAC &
anticardiolipin antibody positivity group.
Table 5

















1 Hb in gm(mean ±SD) 9.58±2.34 9.42±1.79 0.313 NS
Aneamia <10 gm(no.
of pts)








3 15.78% 9 15.51% 0.028 NS
3 ESR in mm/1
hr(mean ±SD)
66.58±35.29 66.03±41.75 0.052 NS
4 ESR  > 50 mm/1 hr
(no. of pts)
11 57.89% 31 53.44% 0.338 NS
5 CRP positivity(no. of
pts)
8 42.10% 21 36.20% 0.461 NS
6 T. cholesterol
>200mg (no. of pts)
8 42.10% 25 43.27% 0.076 NS
7 LDL cholesterol
>130mg (no. of pts)
7 36.84% 22 37.93% 0.085 NS
8 Triglycerides
>150mg(no. of pts)
8 42.10% 30 51.72% 0.728 NS
9 HDL cholesterol
<40mg (no. of pts)
4 21.05% 11 18.96% 0.199 NS
10 LAC Study
detected(no. of pts)
4 21.05% 3 5.17% 2.090 <0.04*
11 aCL  positivity(no. of
pts)
15 78.94% 27 46.55% 2.461 <0.02*
12 Complement C3
Low(no. of pts)
8 42.10% 20 34.48% 0.599 NS
13 Complement C4
Low(no. of pts)
2 10.52% 16 27.58% 1.525 NS
14 SLEDAI score(mean
±SD)
19.11±11.32 17.08±9.61 0.764 NS
* Significant (<0.05)
Table 6
Comparison of demographic and clinical parameters - aCL positive Vs aCL negative








1 Age in yrs
(mean ±SD)
22.63±6.34 23.79±6.65 0.893 NS









3 5.76% 1 2.08 0.946 NS
5 Digital
gangrene/DVT
4 7.69% 2 4.16% 0.742 NS
6 Heart rate/min
(mean ±SD)




6 11.53% 9 18.75% 1.009 NS
7 Hypertension
(no. of pts)
8 15.38% 7 14.58% 0.112 NS
Tables 6 &7 shows that valvular heart disease was more common in those patients
with anticardiolipin antibody positivity. But there was no significant relationship between
anticardiolipin antibodies and other cardiac manifestations like pericardial disease, systolic &
diastolic left ventricular dysfunction, global hypokinesia due to myocarditis and pulmonary
hypertension.
Table 7













1 Hb in gm
(mean ±SD)
9.21±2.27 9.15±1.59 0.152 NS
Aneamia <10 gm
(no. of pts)








8 15.38% 7 14.58% 1.009 NS
3 ESR in mm/1 hr
(mean ±SD)
68±36 65±40 0.395 NS
ESR  > 50 mm/1 hr
(no. of pts)
32 61.53% 27 56.25% 0.537 NS
4 CRP positivity
(no. of pts)








16 30.76% 19 39.58% 0.923 NS
7 Triglycerides
>150mg(no. of pts)
28 53.84% 26 54.16% 0.032 NS
8 HDL <40mg (no.
of pts)
10 19.32% 11 22.91% 0.452 NS
9 Complement C3
Low(no. of pts)
23 44.23% 16 33.33% 1.116 NS
10 Complement C4
Low(no. of pts)
15 28.84% 12 25% 0.433 NS
11 Valvular disease 15 26.92% 4 8.33% 2.417 <0.02*
12 Sys. LV
dysfunction
2 3.84% 1 2.08% 0.516 NS
13 Diast. LV
dysfunction
4 7.69% 2 4.16% 0.742 NS
14 Global hypokinesia 2 3.84% 1 2.08% 0.516 NS
15 Pericardial disease 13 26.92% 9 18.75% 0.970 NS
16 PUL. HT 4 7.69% 5 10.41% 0.476 NS
17 SLEDAI
score(mean ±SD)
18.63±10.67 17.75±10.69 0.412 NS
* Significant (<0.05)
Table 8





Cardiac disease     .00










Variables in the Equation















































































Binary logistic Regression for Valvular heart disease -Classification Table
Observed Predicted
Valvular heart disease Percentage
Correct
.00 1.00
 Valvular heart disease    .00
                                       1.00









Variables in the Equation














































































   *significant (p <0.05)
In table 9 binary logistic regression analysis showed that there was no significant
relationship between dependent (cardiac involvement) and other independent covariates (BP,
CRP, LDL, TGL, HDL, LAC, C3, C4, aCL positivity, abortion).
But  in  table  11,  the  analysis  showed  that  history  of  recurrent  abortion  and  aCL
positivity were significant predictors for having valvular heart disease in SLE patients. Other
variables (hypertension, positive CRP, dyslipidaemia and C3) were not significantly related
to the valvular heart disease.   SLE patients who have   recurrent abortions and aCL positivity
are  19  times  and  4  times  more  likely  to  have  valvular  heart  disease  respectively  when
compared to their counterparts.
























































Figures in parentheses indicate ‘P’ value; *: Significant (P ? 0.05);
**: Very significant (P ?0.01)
The mean carotid IMT in the study group (n=70) was (mean±SD) 0.573± 0.093
mm and in the control group (n= 20) 0.47± 0.056 mm (p value <0.001). Patients with lupus
(mean age 23.28±7.07, disease duration 30.91±24.24 months) exhibited a significantly
greater IMT than controls (mean age 22.75±3.22 yrs). Carotid plaques were seen in 4 (5.71%)
cases.  None  of  the  control  population  had  plaques  (p  =NS).  On bivariate  analysis,  the  IMT
was significantly affected by age, systolic blood pressure and LDL cholesterol (table 12).
DISCUSSION
DISCUSSION
SLE is a multisystem disorder and the manifestations can be variable. In atypical
cases the diagnosis may be missed if the index of suspicion is not high.  The present study
was done on 100 SLE patients conforming to the 1997 revision of ACR 1982 classification
criteria. There were 95 females and 5 males. The Female to Male ratio was 19:1. Indian series
by Malaviya et al (104) had a female to male ratio of 8:1. There are reports from southern
and eastern part of India, similar to the observations in the present study (100, 103).
The age of the patients varied from 11 years to 45 yrs. The mean age of the
patients was 23±6.77 years. Disease onset was in the second or third decade was common.
Median age at disease onset was 20.83±6.29 years. Masi et al and Hochberg et al observed a
median age of disease onset at 31 and 30 years respectively (105). In India, Binoy J. Paul et
al and Ghosh B et al noted a median age of onset of 21.6 and 26.5±9 years respectively
(101,103). Almost one quarter of patients had childhood onset of disease. The mean disease
duration was 2.5±2 years. Majority of our study cases had short disease duration and renal
involvement was found in 32 patients (32%).
Musculoskeletal and mucocutaneous involvement were the commonest clinical
manifestations noted in the study group as reported in studies from India and abroad (100,
104).
Symptoms like dyspnea on exertion (27 %), chest pain (15%), palpitation (21%)
and leg swelling (19%) were present. These symptoms may also occur due to other causes
(respiratory, anaemia, renal and steroid use). Hypertension and tachycardia were present   in
15% of cases. Hypertension is closely related to disease duration and nephropathy. Cardiac
failure  was  present  in  4% of  patients.  Cardiac  tamponade  was  seen  in  one  patient.  Systolic
thrill in the mitral area was present in one patient. On auscultation muffled heart sound was
present in5%, loud P2 in 7%, third heart sound in 15%, fourth heart sound in 4%, mid
systolic click in the mitral area in 5%, pan systolic murmur in the mitral area in 4% and
pericardial rub was heard in 3% of patients. Clinical cardiac manifestations were infrequent
in our study which was similar to the study by Ramonda R et al (106).
ECG abnormalities were detected in 25% of cases comprising sinus tachycardia in
16%, ST-T changes in 5%, conduction abnormalities in 3 % of cases (AVNRT, RBBB and
complete heart block in each 1 patient), RVH pattern and low voltage complexes were
present in each 1% of patients. This is in agreement with the findings of Uri Elkayam et al
(107) except for sinus tachycardia which was comparatively more frequent in our study.
Ghosh B et al (103) found sinus tachycardia in 22 patients (26%) followed by non-specific
ST-T change in three patients (4%).
On echocardiogram cardiac abnormalities were found in 41% of patients which
was similar to Gentile et al.  (46.3%) and B Ghosh et al (46%) (103, 108). Echo findings
comprised of pericardial effusion in 22%, valvular abnormalities in 19% and over all
myocardial involvement in 10% of cases.
Pericardial disease is usually asymptomatic, and is generally diagnosed by echo.  It
was the most common lesion in the present study. Mild  pericardial  effusion  was  present  in
15%, moderate in 3% and large effusion in 4% of cases. Cervera R et al (7) in a case control
prospective study found pericardial effusion in 27% of patients (20% mild effusion and 7%
moderate to large effusion). There are rare reports of pericardial tamponade in SLE.
Pericardiocentesis was done for 1 patient for large pericardial effusion with tamponade and
pericardial strands noted in another one. Evaluating several clinical studies in the literature,
Doherty and Siegel (5) found a 25.6% prevalence of pericarditis in 1,194 patients with SLE,
but a prevalence of 62.1% in the 254 cases at autopsy.
Compared to the present study (10%), Cervera R et al (7) found increased
frequency (20%) of myocardial abnormalities. In the present study, global hypokinesia with
decreased EF due to myocarditis was found in 3% of patients. LV diastolic and systolic
dysfunction was found in 6%, 3% cases respectively. 2% of patients had mild to moderate
concentric LVH. Kalke S et al (59) observed more or less similar frequency in their 54 SLE
patients.
Myocarditis is an uncommon, often asymptomatic manifestation of SLE with a
prevalence of 8 to 25% in different studies. Lupus myocarditis can be diagnosed by clinical
suspicion and echocardiographic evidence of impaired LV EF and wall motion abnormality,
if other etiologies such as viral and ischemic cardiomyopathy are excluded.
 Involvement of the mitral valve was most commonly encountered followed by
aortic valve (62). However, any valve or multivalvular affection can occur. Functionally,
valvular regurgitation was reported to occur in up to 74% of patients, 7~41% of cases having
moderate to severe regurgitation, while valvular stenosis was seen in only 3~4% of patients
(62) and usually accompanies regurgitation. Valvular  abnormalities  was  seen  19%  of  our
patients, comprising mitral valve involvement in (15%), followed by tricuspid (9%) and then
aortic valve (3%).Mild, moderate and severe mitral regurgitation was found in10%, 2%, and
1% of cases respectively. Mitral valve thickening was seen in 1%. Mitral valve prolapse was
noted in 5% of cases. None had stenotic valvular lesions or vegetations. Similar findings had
been reported by Ghosh  B  et  al (103) in a recent study. The incidence of this type of
endocarditis has progressively declined during the last four decades, because of the use of
more efficient therapies for SLE in recent years, compared with the initial period of 1920 and
1930 when the lesions were first described. Some people attribute the possible reduction in
the incidence of these lesions in lupus to an increase in corticosteroid use (5). Also attributed
to steroids is a possible reduction in valvular dysfunction, because they promote healing of
scars caused by veruccous lesions, which would result in fibrotic retraction of valve cusps
(63).
There exists no relationship between cardiovascular status of SLE patients, disease
duration and disease activity (SLEDAI scores). Lolli  C  et  al (109) also observed similar
findings as by Ghosh B et al from India (103).
There was no statistically significant difference in the parameters (table 2 & 3)
between the patients who had cardiac involvement and those with normal cardiac status
including anticardiolipin antibodies. Higher percentage of recurrent abortions, anticardiolipin
antibodies and LAC were present in patients with valvular heart disease (p value < 0.05)
(table4, 5).
In the present study, the frequency of anticardiolipin antibodies was 52% while
two studies from our country, the north and from Madras reported 28% and 41% respectively.
When patients were divided on the basis of anticardiolipin antibodies, valvular abnormalities
was higher in the positive group (p value < 0.02) (table 7) and no significant difference was
found with other cardiac manifestations including pulmonary hypertension and other
parameters between the groups. This is in agreement with the findings of Gentile et al (108)
in which pericardial effusion was detected in 19 patients without any statistical difference
between aPL positive and negative groups, but more frequent valvular involvement being
noted  in  aPL  positive  patients.   But  as  opposed  to  Gentile  et  al  there  was  no  significant
difference in myocardial involvement between the groups (table 7). Some studies also have
suggested an association between the valvular disease and antiphospholipid antibodies (6, 7,
80). However, other reports have not confirmed the relationship between antiphospholipid
antibodies and valvular heart disease (8, 110).
Binary logistic regression analysis (table 10 & 11) showed that history of recurrent
abortions and aCL positivity were significant predictors for valvular heart disease in SLE
patients. SLE patients who have   recurrent abortions are 19 times and those who have aCL
positivity are 4 times more likely to have valvular heart disease, compared to their
counterparts.
Dyslipidemia is a significant problem in SLE. Untreated SLE is associated with
endogenous dyslipidemia, increased very low density lipoprotein (VLDL), triglycerides, low
high-density lipoprotein (HDL) levels, and altered chylomicron metabolism. Treatment with
steroids is associated with increased low density lipoproteins and triglyceride concentrations.
Dyslipidemia was present in half of our patients (54%). Elevated total cholesterol in 44%,
hypertriglyceridemia in 54%, increased low density lipoproteins in 35% and low high-density
lipoprotein (HDL) levels in 21% were noted.
Jimenez  S.  et  al. (94) noted in their study that SLE patients had a significantly
higher prevalence of hypertension (31%) and hypercholesterolemia (38.6%) than primary
APS patients and controls, and higher incidence of hypertriglyceridemia (31.4%) than
controls. SLE patients had higher total cholesterol, triglycerides and apolipoprotein B levels
than controls at the time of ultrasound study. A recent study from eastern India (103) reported
dyslipidaemia in 49 SLE patients (60%) in the form of high triglyceride (32%), high total
cholesterol (26%), low HDL (48%) and high LDL (36%).
The mean carotid IMT in the study group (n=70) was (mean±SD) 0.573± 0.093
mm and in the control group (n= 20) 0.47± 0.056 mm (p value <0.001). Contrary to some
western studies, the frequency of carotid plaques was less (5.71%) and the patients with lupus
exhibited a significantly greater IMT than controls. This was in full agreement with Bhatt SP
et al from India and Zhang CY et al from China (96).
Bivariate analysis (table 12) showed that age, systolic blood pressure and LDL
cholesterol were independently related to increased carotid IMT which was similar to the
study  by  Bhatt  SP et  al.  Disease  duration  did  not  correlate  with  carotid  IMT in  the  present
study as opposed to that of Bhatt SP et al., where disease duration had a positive correlation
with carotid IMT. There was no relation between anticardiolipin antibodies and the carotid
IMT which was similar to the study by Jimenez S. et al (94).
CONCLUSION
CONCLUSION
1. Pericarditis was the most common observation followed by valvular heart disease.
2. Myocarditis, conduction abnormalities, impairment of systolic and diastolic function
and pulmonary hypertension occur less frequently.
3. Significantly higher number of patients had valvular heart disease in the
anticardiolipin antibody positive group.
4. SLE patients with anticardiolipin antibody positivity are 4 times more likely to have
valvular heart disease, compared to their counterparts.
5. The risk of valvular heart disease is 19 times higher in lupus patients who also have
secondary antiphospholipid antibody syndrome with history of recurrent abortions.
6. Dyslipidemia was found in half of the patients.
7. Patients with lupus exhibited a significantly greater IMT than controls.
8. The carotid IMT was independently related to age, systolic blood pressure and LDL
cholesterol.
9. There was no relation between anticardiolipin antibodies and the carotid IMT.
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APPENDICES
ABBREVIATIONS
aCL IgM, IgG Anticardiolipin antibody IgM, IgG




AVNRT Atrioventricular nodal reentry tachycardia
C3,C4 Complement
CAD Coronary artery disease
CRP C-reactive protein
DLE Discoid  Lupus Erythematosus
dsDNA Double stranded DNA
IMT Intima-media thickness
LAC Lupus anticoagulant
MCTD Mixed connective tissue disease
SLE  Systemic Lupus Erythematosus
Sm Ab Anti –Smith antibody
TEE Trans esophageal echocardiography
TTE Trans thoracic echocardiography
PATIENT CONSENT FORM
  Study title       : A study on cardiovascular manifestations in lupus
                                        patients”
PROFORMA
CARDIOVASCULAR MANIFESTATIONS OF SLE
NAME:                                                          AGE/SEX:                                   OP/IP No:
RCC No    :





Fever                                   Malaise                                  Fatigue                      photosensitivity
Malar rash                           Discoid lesion                  Palatal ulcer                           Alopecia
Purpura                                Striae                         Vasculitic ulcer                       Raynaud’s
Gangrene                             Arthritis -poly                         Pauci                              Arthralgia
Mayalgia                              Weakness                              Headache                        visualsym
Psychosis                              Seizures                                 insomnia                       Chest pain
Palpitation                             Dyspnea                                Syncope                      Pedal edema
Cough                                    Expectoration                       Hemoptysis                  Hematuria
Periorbital edema                  Facial puffiness                     Oliguria
OTHERS
PAST HISTORY:                                                                           PERSONAL:
TREATMENT HISTORY:
PHYSICAL EXAMINATION:
Fever                Aneamia        clubbing         cyanosis      LN       PE           JVP
MUCOCUTANEOUS                                                                                  OTHERS
PULSE                                                    BP                                                 RR
CVS                                                        RS                                                  ABDOMEN
CNS                                                        MSS:
INVESTIGATIONS:
Hb                    TC                   DC                  ESR 1 hr           Platelets                  BT         CT
Urea            Cr                   Uric acid             Sugar              T.Bilirubin            ALT           AST
SAP                  LDH               CPK           Electrolytes    Na                  K            HCO 3      Cl
Lipid profile
Urine R/E                                                          PCR                                           24 hrs protein
ANA                                                                 Anti dsDNA                                     Sm Ab
 LAC                                                                     aCL                     Complement
CRP
ECG                                                                                         CXR PA View




NSAIDS                                                STEROIDS                Pulse                            Oral
























1 20 F 49958 4m dyspnea, palpitation nil nil 86 110/80 8.2 1.6 70  P
2 25 F 46284 3yr chest pain,dysnea yes nil 110 100/70 5.6 3.14 145 p
3 18 M 49937 2yr nil nil 82 110/70 11.2 1.6 55  p
4 15 F 49992 3m nil nil 102 120/80 9.8 1.2 40  p
5 15 F 49963 3m nil nil 122 120/70 8.7 0.85 43  n
6 19 F 47327 4yr dyspnea, palpitation nil 86 116/70 12 1.66 45  P
7 22 F 49880 1.5yr chest pain,PE, palpitation nil 96 130/90 12.2 1.4 85  P
8 20 F 44990 6yr nil nil 96 100/70 10 1.32 25  p
9 26 F 42505 6yr dyspnea, palpitation nil 80 110/70 11.3 1.15 10  n
10 24 F 47565 6yr PE,palpitation nil 90 90/60 8.3 3.34 102 P
11 29 F 49108 3yr nil gangrene Lt. hand 92 110/70 6.8 0.55 80  P
12 22 F 49970 2yr nil nil nil 92 100/70 9.2 1.4 50  P
13 32 F 49607 1yr
dyspnea, palpitation,chest
pain
nil 74 84/66 11.8 0.95 28  n
14 23 F 50057 3m nil nil nil 102 90/66 9 2.24 42  n
15 29 F 48313 1yr
dyspnea, palpitation,chest
pain
nil nil 88 96/74 7.8 1.2 65  n
16 19 F 48397 2yr nil gangrene toes 92 140/80 14.3 1.95 34  n
17 19 F 50086 6m
dyspnea, palpitation,chest
pain
nil 96 112/70 11.4 1.24 20  n
18 36 M 49169 3yr dyspnea, PE nil 100 120/70 8 2.37 128 n
19 32 F 48556 3yr dyspnea nil nil 82 110/80 8.2 1.8 25  n
20 22 F 40603 4m PE nil 96 110/76 11.4 1.75 95  n
21 21 F 50178 1yr nil nil 78 90/70 9.6 1.8 120 n
22 19 F 48398 9m dyspnea nil 102 110/80 7.9 1.36 125 p
23 22 F 44347 4yr nil nil nil 82 100/80 9.4 0.5 56  p
24 20 F 50072 3yr nil nil 80 120/76 7 1.45 98  n



















26 18 F 47112 2yr nil nil 86 110/80 10 2.6 46  P
27 18 F 47643 1.5yr nil nil 84 114/80 10 0.85 52  n
28 16 F 46142 6yr nil nil 98 100/70 8.5 1.6 80  n
29 24 F 45302 7yr nil nil 76 110/76 12.7 2.79 40  p
30 37 F 50331 6m PE nil nil 80 96/50 6.8 0.4 102 n
31 18 F 50251 3m chest pain, dyspnea, PE preterm nil 96 140/116 6.9 1.45 80  p
32 20 F 50344 1m nil nil 78 110/80 8.1 0.92 58  p
33 21 F 50402 2.5yr PE nil nil 78 110/70 8 2.1 80  n





96 110/90 4 1.14 150 n
35 16 F 50390 4m
chest pain, dyspnea,
PE,orthopnea
nil 90 90/70 8.4 3 76  n
36 16 F 48461 2yr dyspnea , palpition nil 126 140/86 8 1.92 105 p
37 33 F 50454 1yr nil nil nil 92 110/70 9.3 1.91 80  n
38 20 F 45625 9yr nil nil 76 110/70 10.7 1.7 25  n
39 15 F 49310 7m nil nil 90 110/70 7.4 1.55 120 n
40 21 F 50508 4yr dyspnea nil 78 116/70 10.5 1.01 33  n
41 21 F 49701 1.5yr dyspnea nil 100 90/60 5 1.82 85  n
42 24 F 50517 4m PE nil 74 110/80 9.8 1.2 50  n
43 18 m 49628 7m nil nil 82 110/90 8.4 1.56 47  n
44 25 F 49978 4.5yr dysnea nil 80 140/96 12.4 2 8 p
45 30 F 45373 3yr nil nil nil 76 110/80 11 1.4 65  p
46 25 F 50547 3m nil nil nil 78 110/70 8.5 0.64 54  n
47 18 F 50529 3yr
chest pain, dyspnea,
palpitation
DVT Lt leg 90 116/80 9.4 1.65 42  n
48 25 F 50564 2m dyspnea nil 116 122/80 8 1.56 135 n
49 24 F 50531 4m chest pain, palpitation yes nil 110 110/80 6.6 1.67 82  n





















51 17 F 50636 1yr nil nil 76 120/80 11 1.56 10 n
52 20 F 49538 2yr palpitation nil 75 110/80 11.8 1.82 10 n
53 22 F 49641 3m PE,dyspnea nil 90 100/80 6 1.6 40 n
54 32 F 50643 6m nil nil nil 102 106/80 9 1.6 135 n
55 23 F 49985 6m palpitation nil 85 110/80 7.8 1.8 85 p
56 18 F 44341 4yr nil nil 76 110/80 9.8 1.93 100 p
57 16 M 46417 3yr nil nil 76 100/70 11.4 1.3 45 n
58 22 F 41235 1.5yr Chestpain nil 88 116/80 12.2 2.26 43 n
59 23 F 46939 4yr dyspnea nil 76 100/70 10.3 2.11 70 n
60 25 F 48459 2yr nil nil 88 140/70 11.2 2.01 35 n
61 30 F 44263 1.5yr nil nil nil 76 124/80 9.2 4.53 33 n
62 40 F 43441 5yr nil nil nil 74 130/90 7 0.45 98 n
63 15 F 49266 1yr nil nil 76 110/80 8 1.24 56 n
64 22 F 48754 2yr dyspnea nil 70 110/70 8.4 1.76 114 n
65 37 F 50363 1.5yr PE nil nil 82 106/80 9.8 1.62 80 n
66 25 F 48491 2yr nil yes nil 78 110/70 11.4 2.75 20 n
67 22 F 41516 3.5yr nil nil nil 76 110/76 10.7 2.77 30 n
68 20 F 44138 5yr dyspnea nil 78 110/82 6.7 2,74 120 p
69 36 F 46304 3yr nil nil nil 80 126/80 10.2 0.85 95 p
70 27 F 50654 2yr nil yes nil 74 130/80 8.8 1.53 65 p
71 38 F 43814 5yr nil nil nil 78 120/78 12 2 20 n
72 18 F 47628 2yr nil nil 92 96/70 10.8 1.5 15 p
73 24 F 49424 6m dyspnea, palitation nil nil 110 100/70 7 4.26 68 n
74 20 F 50727 2yr chest pain, dyspnea nil 88 110/70 11.2 1.68 35 p





















76 38 F 46952 3yr nil nil nil 84 140/80 8 1.9 34 p
77 34 F 47403 7yr nil nil nil 98 70/60 8.2 2.88 67 p
78 27 F 44660 5yr chest pain, palpitation nil nil 86 100/70 10 3.78 25 n
79 27 F 50798 1yr nil nil nil 102 110/80 9.8 1.37 65 n
80 25 F 41105 5yr palpitation nil nil 90 90/60 9.4 1.56 5 n
81 21 F 46800 5yr palpitation nil 82 160/110 10.2 2.5 20 p
82 18 F 48442 3yr nil nil 70 110/70 12.6 2.76 65 n
83 37 F 49675 5yr nil nil nil 76 130/86 11 2.6 34 n
84 12 F 50287 4m nil nil 88 90/60 9 1.56 112 n
85 11 F 50800 8m dyspnea nil 82 110/70 8.2 0.212 110 n
86 30 F 42698 8yr nil nil nil 76 140/86 9.2 1.9 30 n
87 27 M 46708 5yr nil nil 87 130/90 9.8 1.6 32 p
88 22 F 50812 5yr chest pain, palpitation nil 88 130/90 9 1.72 20 n
89 32 F 47858 4yr nil nil 76 160/100 7.2 1.8 95 p
90 20 F 47303 3yr dyspnea,palpitation nil 79 120/82 11 1.68 10 p
91 17 F 50955 6m PE nil 92 110/80 9 0.87 152 n
92 13 F 51046 2yr PE nil 86 110/70 6.2 1.58 95 P
93 29 F 51037 3m nil nil nil 70 100/80 9.8 3.12 116 n
94 21 F 51067 2yr PE nil 82 110/80 8.4 1.52 130 P
95 24 F 51009 5yr palpitation, dyspnea, PE gangrene digits 110 146/96 9.4 0.44 96 p
96 20 F 47971 2.5yr nil gangrene digits 84 110/76 8.8 2.4 25 p
97 28 F 50963 3yr nil nil nil 90 110/70 10.4 1.84 100 n
98 15 F 51034 1yr palpitation, dyspnea, PE nil 80 160/110 10.6 1.69 78 n
99 21 F 51061 6m PE 1 abortion nil 78 124/80 4 1.8 70 n
100 32 F 48810 4yr chest pain, palpitation nil nil 76 130/84 6.3 2.8 82 n
SL.
NO T.Chol









1 200 116 220 40 p p NG NG MP MP L N N N
PE+, MR trivial,Global hypokinesia of
LV, EF 50%
2 180 114 142 38 P BLP P NG MP MP N L ST N PE+, MR &AR Mild
3 130 67 124 40 P BLP P  NG  MP  MP  N  N N N N
4 180 80 226 56 p P NG  NG  MP  MP  N  N N N PE+
5 208 129 176 44 P BLP P NG NG NG N N ST N N
6 166 93 126 48 p p NG NG MP MP L L ST N N
7 219 153 119 42 p NG NG NG MP MP L N ST B/L PL. Effusion trivial MR
8 130 76 70 40 p P NG NG NG NG L L
RBBB,T?inV2-
V5&II,III,aVF
cardiomegaly severe PHT,RA&RV dilated, PE
9 156 86 110 48 P BLP P P MP MP L N RVH N
RA&RV dilated,TR mild,PG 50mmHg,
PHT mod
10 280 216 140 36 HP p NG NG NG NG L N N N Severe MR, PHT &TR
11 213 121 189 54 HP P NG NG MP MP L L ??I,II,Avl &v1-v4 B/L PL. Effusion N
12 174 98 166 43 P NG NG  NG  MP  MP  N  N N N N
13 258 180 164 45 HP P NG  NG  MP  MP  N  N N Lt.PL.Effusion
MR,AR,TR mild PHT mod.,mild conc
LVH
14 163 90 287 39 P HP NG NG NG NG N N N N N
15 208 130 164 44 P P P NG NG NG L L N N
Global hypokinesia of LV,mod LV
dysfunt,EF 46%
16 252 190 91 44 P NG NG P MP HP N N N N trivial MR
17 165 76 250 41 P MP  NG  NG  MP  MP  N  N ST N Massive PE with tamponade
18 218 118 343 46 P BLP P  NG  MP  NG  N  N N N N
19 183 84 280 43 P NG NG NG NG NG N L N N mild PE
20 113 57 131 34 P BLP P  NG  MP  MP  N  N N N N
21 194 122 125 47 P P NG NG NG NG L L N N N
22 170 84 262 36 P NG NG NG NG NG N N ST N MVP, Tachycardia
23 205 123 184 46 P NG NG P NG MP N L N N N
24 265 163 253 52 P NG NG NG NG NG N N ST N N
25 246 134 498 38 P P P NG NG MP L L ST cardiomegaly mod. PE
SL.
NO T.Chol









26 229 147 176 47 P P NG NG MP MP L L N N N
27 154 83 132 45 p BLP P NG NG NG N N ST N trivial PE
28 470 210 245 48 p NG NG NG NG NG N N N N Mild diastolic LV
29 160 70 195 52 p BLP NG NG MP MP L N N N N
30 245 145 275 40 p p P NG MP NG L N N N N




32 146 81 92 47 p P NG NG NG NG N N N N N
33 200 97 320 43 HP p P NG MP MP N N ST increased BVM N
34 176 109 124 42 P P P NG MP MP L N N N N






36 165 80 250 38 p P NG NG NG NG L L AVNRT N N
37 233 168 141 37 p P NG NG MP MP N N N N mild TR
38 239 164 126 50 p P P NG MP MP N N N increased BVM N
39 154 70 250 38 p p NG  p  MP  HP  L  N ST N Mild PE, mod MR,LVH
40 224 165 74 44 NG NG NG NG NG NG N N N Rt.pl.effusion N
41 186 114 97 52 p NG NG NG MP MP N N N Rt pl effusion mod. PE
42 165 101 94 45 p P P NG NG NG N N N N N
43 224 156 425 37 p NG P NG NG NG N N N N N
44 228 114 245 65 HP NG NG NG MP MP N N N N N
45 198 116 161 60 p BLP P NG MP BLP N N N
straightening of lt heart
border
thickened mitral valve , mild
MR
46 221 134 317 54 P P NG NG MP MP N N N N mild MR
47 194 112 205 52 P P NG P BLP BLP L L N N
mild global hypokinesia, EF
50%
48 169 76 177 48 P P NG NG NG NG N N N N N
49 155 78 238 46 p P NG NG MP MP L N N B/L PL. Effusion MVP,mild MR
50 130 57 186 47 p P NG NG MP NG L L N N N
SL.
NO T.Chol









51 157 90 78 52 p P P NG NG NG L N N N N
52 199 133 119 42 p p P NG NG MP L N N N N
53 181 112 134 42 p NG NG NG MP MP N N ST cardiomegaly PE,EF 62%
54 270 165 362 45 p NG NG NG NG NG L L ST B/L PNEUMONITIS N
55 162 90 99 52 p P NG NG NG NG N N N N N
56 147 70 281 50 p BLP P NG NG NG N N N N N
57 212 151 116 48 p P P NG NG NG L L N N N
58 216 124 341 43 P P NG NG NG NG N N AVD, CHB N mildTR, Trivial AR
59 187 117 151 40 p P P NG NG NG N L N N N
60 178 116 109 50 p NG NG NG NG MP N N ??v5-v6 N mild PHT, RA &RV dilated, TR trivial
61 138 67 133 54 p NG P NG MP MP N N N N N
62 209 150 112 37 p NG NG NG NG NG N N N N N
63 190 102 154 47 p P NG NG NG BLP N N N N N
64 266 164 224 38 p P NG NG NG NG L N N N Mild PE
65 170 96 368 50 p P P NG NG NG N N N N N
66 234 155 123 54 p NG NG NG NG NG N N N N N
67 294 212 154 45 p P P p MP MP N N N N N
68 240 124 387 39 p p NG NG NG NG N N N N mod.PHT
69 234 154 182 43 p NG NG NG NG NG N N N N MILD PHT
70 212 145 98 47 p P P p  MP  BLP  N  N N N MOD. MR
71 270 195 177 40 N NG P NG NG NG N N N N N
72 153 84 168 42 p NG P NG NG NG N N N N N
73 187 110 118 53 p NG NG NG NG NG N N N B/L PL. Effusion large PE,no tamponade,stands+
74 166 106 83 44 p p NG NG NG NG N N N N
severe PHT,RA&RV  pul A dilated,TR
mod
75 110 56 205 48 p p NG NG NG NG N N N N N
SL.
NO T.Chol









76 243 176 144 38 NG BLP NG NG NG NG L L N N N
77 198 125 152 42 p NG NG NG NG NG N N ST-T CHANGES B/L PL. Effusion MILD PE
78 242 154 203 48 p P NG NG NG MP N N N N N
79 217 124 273 35 p NG P NG NG NG L L N N N
80 165 77 201 50 P P NG NG NG NG N N N N N
81 245 174 174 36 P P P NG NG NG N N N N N
82 187 118 146 39 p BLP P  NG  NG  MP  L  L N N N
83 145 87 233 40 HP HP NG NG MP MP N N N N N
84 122 50 130 46 HP HP NG NG MP BLP L L N N N
85 228 118 242 56 p HP NG NG NG MP L L N N MILD PE,MVP
86 236 156 144 51 p NG P NG NG NG N N N N N
87 176 102 134 47 p NG NG NG NG NG N N N cardiomegaly MILD MR. MVP. MILD PE
88 233 167 101 46 p BLP P NG NG NG L N N N N
89 280 207 176 38 p NG NG NG NG NG L N SR, T Inv. V1-V3 N PE
90 248 170 165 45 p NG NG NG NG NG N N N N N
91 166 99 132 41 p P NG NG NG NG N N N N N
92 172 103 126 44 P P NG NG NG NG L L ST N N
93 243 160 156 52 p P NG NG NG NG N N N N N
94 212 112 267 35 HP p NG NG NG MP L L N N N
95 256 146 234 37 p p P P NG NG L N N N N
96 253 156 256 47 p P NG NG NG NG L L N N MILD PE
97 222 148 97 52 p p NG NG MP MP N L N N N




99 210 130 237 40 p p NG NG NG NG L N ST Large cardiomegaly large PE
100 187 114 145 45 p NG NG NG MP MP L N N N
MVP, MR-mild.ASD, TR, PHT-mild.
RA,RV slightly dilated
S.




52 0.6 2 10
53 9 10
54 0.64 43 25
55 9 10
56 0.65 7 7.5
57 0.45 13 10
58 0.5 10 12.5
59 9 10
60 0.6 7 10
61 0.6 4 7.5
62 0.8 7 10
63 0.47mm 11 10
64 0.61 14 10
65 0.47 11 7.5
66 8 10
67 0.61 4 5
68 0.5 7 7.5
69 0.72mm,laque in lt CCA 6 7.5
70 16 15
71 0.65mm,plaque in rt. C bulb 12 15
72 0.54 17 17.5
73 0.56 12 10
74 0.6mm, plaque rt. C bulb 11 12.5
75 0.58 16 15
76 35 22.5, dexa
77 0.5 43 25
78 9 10
79 0.6 32 30, pulse
80 0.56 6 10
81 0.56 10 15
82 12 15
83 0.85 15 12.5
84 0.42 17 15
85 0.4 24 17.5
86 11 12.5
87 11 20
88 0.56 9 10
89 0.75 14 15
90 0.52 15 17.5
91 0.4 13 15
92 0.42 33 25
93 0.61 14 15
94 0.6 22 17.5
95 31 20
96 0.56 14 12.5
97 19 15
98 35 25
99 40 30, dexa
100 0.61 7 10
S.
no
CAROTID IMT in mm SLEDAI steroid dose mg
 1 0.54mm 16 15
2 0.65mm 23 17.5
3 0.56mm 15 10
4 0.48mm 7 17.5
5 0.5mm 9 10
6 14 22.5, pulse, dexa
7 0.65mm 41 30
8 0.45mm 17 15, dexa
9 0.55mm 6 7.5
10 0.4mm 24 20
11 0.75mm,plaque rt CCA 42 45, dexa
12 29 30, dexa
13 0.72mm 10 10
14 11 12.5
15 0.6mm 12 15
16 0.45mm 27 17.5
17 16 30
18 0.7mm, plaque+ LT C bulb 22 15
19 0.58mm 16 20
20 13 12.5
21 0.6mm 23 25
22 27 15
23 0.64mm 12 12.5
24 21 10
25 0.68mm 37 20
26 0.48mm 32 12.5
27 0.58mm 24 15
28 0.47mm 15 10
29 0.55mm 11 12.5
30 0.78mm 31 15, dexa
31 18 15
32 13 10
33 0.59mm 19 17.5, dexa
34 26 27.5, pulse
35 0.46 22 30, pulse
36 0.58mm 45 25
37 20 15
38 0.64mm 21 20
39 0.47mm 45 40
40 9 12.5
41 8 10
42 0.6mm 19 17.5
43 0.48mm 12 15
44 10 10
45 0.62mm 15 15
46 0.59 16 12.5
47 0.53 36 30
48 0.5 30 22.5, dexa
49 34 15
50 0.62mm 27 20
CAROTID INTIMA MEDIAL THICKNESS IN CONTROL GROUP
S.no age sex Controls -
CAROTID IMT
in mm
1 30 M 0.35
2 22 M 0.5
3 21 F 0.45
4 22 F 0.5
5 23 F 0.5
6 22 F 0.45
7 20 F 0.5
8 22 F 0.55
9 23 F 0.45
10 22 M 0.5
11 23 F 0.55
12 18 F 0.42
13 19 F 0.48
14 21 F 0.45
15 27 F 0.5
16 22 F 0.45
17 30 F 0.55
18 25 F 0.48
19 19 F 0.35
20 24 F 0.42

